antibiot
current
phase
ii
iii
review
respect
util
spectrum
activ
mani
agent
treatment
gram
posit
infect
new
deriv
exist
antibiot
class
thu
provid
much
need
quantum
jump
away
establish
resist
mechan
consequ
next
year
novel
antibiot
entir
new
mechan
action
destin
reach
clinic
bacteri
genom
hail
solut
identifi
new
antibacteri
strategi
tremend
impact
genom
genom
base
technolog
discoveri
new
antibacteri
target
illustr
howev
progress
novel
genom
deriv
target
identifi
develop
candid
proven
except
challeng
process
exemplifi
small
number
novel
mechan
agent
current
develop
complex
deliv
new
antibiot
post
genom
era
illustr
along
perspect
potenti
solut
key
research
hurdl
enhanc
facilit
discoveri
new
class
antibiot
despit
vast
amount
press
profession
lay
journal
relat
molecular
diagnost
major
work
still
carri
clinic
microbiolog
laboratori
base
upon
convent
technolog
steadi
rise
applic
molecular
techniqu
diagnosi
manag
infect
singl
massiv
applic
molecular
technolog
accumul
applic
variou
area
either
trial
day
day
applic
either
sensit
cost
effect
non
molecular
technolog
perhap
strike
method
influenc
everi
clinic
bacteriolog
lab
use
molecular
technolog
detect
mrsa
plethora
pcr
base
techniqu
detect
meca
gene
target
identifi
staphylococcu
aureu
staphylococc
speci
new
develop
utilis
light
cycler
base
isotherm
amplif
method
appli
characteris
cultur
staphylococci
direct
detect
specimen
theme
direct
detect
specimen
obvious
seduct
offer
prospect
alter
initi
therapi
much
rapidli
convent
cultur
method
notabl
addit
descript
dna
probe
base
pcr
assay
detect
campylobact
spp
faec
assay
utilis
variant
revers
line
blot
hybridis
assay
utilis
immobilis
oligonucleotid
probe
hybridis
label
pcr
product
specimen
technolog
recent
found
number
applic
area
epidemiolog
type
number
advanc
made
applic
particularli
type
mycobacterium
tuberculosi
strain
variabl
number
tandem
repeat
type
use
variou
platform
includ
dna
sequenc
dhplc
one
use
area
would
abil
use
pcr
type
mrsa
recent
evalu
show
yet
pfge
superior
bacteri
speci
identif
consider
interest
recent
applic
rpob
gene
sequenc
found
sensit
specif
appli
mycobacteria
bacillu
enabl
rapid
definit
identif
b
anthraci
tuberculosi
review
would
complet
without
refer
sar
year
valu
avail
rapid
revers
transcriptas
base
dna
sequenc
sar
coronaviru
subsequ
design
rapid
pcr
assay
undoubtedli
help
identif
case
although
sensit
molecular
method
approach
retrospect
sero
convers
method
final
dna
protein
array
potenti
power
tool
within
studi
pathogen
physiolog
micro
organ
moment
complex
expens
rule
routin
applic
diagnost
laboratori
howev
long
first
commerci
base
array
appli
area
diagnosi
quantiti
type
inform
gain
method
plant
vaccin
antibiot
current
phase
ii
iii
review
respect
util
spectrum
activ
mani
agent
treatment
gram
posit
infect
new
deriv
exist
antibiot
class
thu
provid
much
need
quantum
jump
away
establish
resist
mechan
consequ
next
year
novel
antibiot
entir
new
mechan
action
destin
reach
clinic
bacteri
genom
hail
solut
identifi
new
antibacteri
strategi
tremend
impact
genom
genom
base
technolog
discoveri
new
antibacteri
target
illustr
howev
progress
novel
genom
deriv
target
identifi
develop
candid
proven
except
challeng
process
exemplifi
small
number
novel
mechan
agent
current
develop
complex
deliv
new
antibiot
post
genom
era
illustr
along
perspect
potenti
solut
key
research
hurdl
enhanc
facilit
discoveri
new
class
antibiot
despit
vast
amount
press
profession
lay
journal
relat
molecular
diagnost
major
work
still
carri
clinic
microbiolog
laboratori
base
upon
convent
technolog
steadi
rise
applic
molecular
techniqu
diagnosi
manag
infect
singl
massiv
applic
molecular
technolog
accumul
applic
variou
area
either
trial
day
day
applic
either
sensit
cost
effect
non
molecular
technolog
perhap
strike
method
influenc
everi
clinic
bacteriolog
lab
use
molecular
technolog
detect
mrsa
plethora
pcr
base
techniqu
detect
meca
gene
target
identifi
staphylococcu
aureu
staphylococc
speci
new
develop
utilis
light
cycler
base
isotherm
amplif
method
appli
characteris
cultur
staphylococci
direct
detect
specimen
theme
direct
detect
specimen
obvious
seduct
offer
prospect
alter
initi
therapi
much
rapidli
convent
cultur
method
notabl
addit
descript
dna
probe
base
pcr
assay
detect
campylobact
spp
faec
assay
utilis
variant
revers
line
blot
hybridis
assay
utilis
immobilis
oligonucleotid
probe
hybridis
label
pcr
product
specimen
technolog
recent
found
number
applic
area
epidemiolog
type
number
advanc
made
applic
particularli
type
mycobacterium
tuberculosi
strain
variabl
number
tandem
repeat
type
use
variou
platform
includ
dna
sequenc
dhplc
one
use
area
would
abil
use
pcr
type
mrsa
recent
evalu
show
yet
pfge
superior
bacteri
speci
identif
consider
interest
recent
applic
rpob
gene
sequenc
found
sensit
specif
appli
mycobacteria
bacillu
enabl
rapid
definit
identif
b
anthraci
tuberculosi
review
would
complet
without
refer
sar
year
valu
avail
rapid
revers
transcriptas
base
dna
sequenc
sar
coronaviru
subsequ
design
rapid
pcr
assay
undoubtedli
help
identif
case
although
sensit
molecular
method
approach
retrospect
sero
convers
method
final
dna
protein
array
potenti
power
tool
within
studi
pathogen
physiolog
micro
organ
moment
complex
expens
rule
routin
applic
diagnost
laboratori
howev
long
first
commerci
base
array
appli
area
diagnosi
quantiti
type
inform
gain
method
mani
potenti
advantag
gain
use
plant
product
system
recombin
protein
higher
eukaryot
organ
endomembran
system
fold
assembl
recombin
protein
use
protein
chaperon
homolog
mammalian
cell
glycosyl
protein
moreov
offer
potenti
scale
agricultur
proport
offer
possibl
produc
protein
enorm
quantiti
well
prospect
low
cost
import
applic
area
benefit
could
brought
bear
field
vaccin
product
particularli
develop
countri
plant
express
igg
monoclon
antibodi
first
describ
sinc
transgen
plant
proven
extrem
versatil
success
use
antibodi
fragment
igg
secretori
iga
antibodi
latter
alreadi
taken
clinic
trial
consider
amount
work
also
perform
express
antigen
plant
particularli
view
oral
deliveri
date
three
exampl
test
humans
coli
heat
labil
toxin
hepat
b
surfac
antigen
norwalk
viru
capsid
protein
overal
proof
principl
demonstr
product
recombin
pharmaceut
plant
next
step
progress
formal
clinic
trial
importantli
commercialis
first
product
last
year
seen
consensu
emerg
particularli
uk
usa
two
import
area
use
corticosteroid
manag
adult
bacteri
mening
manag
drug
sensit
multidrug
resist
tuberculosi
bacteri
mening
first
randomis
doubl
blind
placebocontrol
trial
adjunct
steroid
adult
show
reduct
proport
patient
unfavour
outcom
vs
p
proport
patient
die
vs
p
benefit
obviou
patient
pneumococc
mening
n
engl
j
med
adjunct
dexamethason
therapi
recommend
adult
suspect
pneumococc
mening
howev
health
careassoci
infect
endem
result
crosstransmiss
relat
inappropri
patientcar
practic
improv
healthcar
worker
hcw
complianc
practic
infect
control
learn
behaviour
scienc
infect
control
profession
play
key
role
identif
prevent
nosocomi
infect
act
observ
educ
ultim
becom
chang
agent
chang
behaviour
shift
social
norm
multipl
level
hcw
commun
among
key
challeng
infect
control
today
although
modif
patientcar
practic
vital
infect
prevent
issu
receiv
littl
attent
medic
literatur
latter
half
centuri
suggest
social
behaviour
could
best
understood
function
peopl
percept
rather
function
real
life
assumpt
gave
birth
sever
model
base
social
cognit
variabl
improv
understand
human
behaviour
cognit
variabl
use
model
includ
knowledg
motiv
intent
percept
threat
outcom
expect
perceiv
actual
behaviour
control
social
pressur
determin
shape
behaviour
acquir
socialis
process
importantli
suscept
chang
social
cognit
model
health
belief
model
health
locu
control
protect
motiv
theori
theori
plan
behaviour
selfefficaci
model
appli
evalu
predictor
health
behaviour
far
none
success
appli
explain
behaviour
field
infect
control
success
strategi
improv
infect
control
practic
result
multidimension
aspect
success
behaviour
chang
well
explain
appli
theori
ecolog
perspect
base
two
key
idea
behaviour
view
affect
affect
multipl
level
influenc
b
behaviour
influenc
influenc
social
environ
level
influenc
healthrel
behaviour
condit
includ
intraperson
interperson
institut
commun
factor
well
administr
support
intraperson
factor
individu
characterist
influenc
behaviour
knowledg
attitud
belief
person
trait
interperson
factor
includ
interperson
process
primari
groupsfamili
friend
peersthat
provid
social
ident
support
role
definit
hcw
influenc
influenti
social
environ
behaviour
often
influenc
peer
group
pressur
social
cognit
theori
state
peopl
learn
experi
also
observ
other
action
result
action
well
model
institut
factor
consid
promot
chang
includ
avail
easi
access
rule
polici
well
technic
inform
structur
help
promot
recommend
behaviour
respons
hcw
individu
group
must
clearli
recognis
defin
commun
factor
social
network
norm
exist
either
formal
inform
individu
group
organis
exampl
hospit
commun
level
would
ward
communitylevel
model
framework
understand
social
system
function
chang
commun
organis
activ
conceptu
framework
commun
organis
model
base
social
network
support
focus
activ
particip
develop
commun
help
evalu
solv
health
problem
public
polici
factor
includ
local
polici
regul
support
practic
diseas
prevent
control
manag
institut
administr
must
openli
support
creation
multidisciplinari
task
forc
address
problem
infect
crosstransmiss
within
ward
hospit
mandat
repres
member
multidisciplinari
institut
team
come
togeth
identifi
problem
develop
strategi
resolv
also
endors
choic
option
taken
mobil
hospit
resourc
need
implement
strategi
base
behaviour
theori
report
experi
multimod
intervent
strategi
chanc
success
singl
approach
promot
programm
focus
one
two
element
similarli
social
model
includ
sever
level
cognit
determin
chanc
success
explain
chang
behaviour
concret
exampl
appli
infect
control
issu
present
studi
need
assess
key
determin
infect
control
practic
behaviour
promot
among
differ
popul
hcw
develop
method
secur
senior
manag
support
implement
evalu
impact
differ
compon
multimod
programm
promot
optim
infect
control
practic
hajo
grundmann
nation
institut
public
health
environ
rivm
bilthoven
netherland
among
potenti
pathogen
microorgan
bacteria
among
enigmat
creatur
virus
small
enough
biochem
mean
molecular
biolog
help
us
get
neartocomplet
understand
aspect
development
lifecycl
bacteria
complex
prokaryot
remot
eukaryot
understand
lifecycl
term
conjug
segreg
govern
reproduct
higher
organ
genet
type
especi
genom
sequencebas
type
provid
insight
genet
popul
structur
bacteria
thu
address
pertin
research
question
taxonomi
evolutionari
genet
microbi
ecolog
identifi
epidem
potenti
bacteria
sinc
evolutionari
converg
parallel
expect
occur
mani
gene
rate
multilocu
approach
yield
classif
heurist
also
epidemiolog
valu
liverpool
school
tropic
medicin
pembrok
place
liverpool
uk
marktaylor
livacuk
filari
nematod
caus
widespread
debilit
diseas
throughout
mani
tropic
region
filari
diseas
includ
acut
lymphang
chronic
hydrocoel
lymphodema
elephantiasi
lymphat
filariasi
skin
diseas
blind
onchocerciasi
recent
research
highlight
role
symbiot
bacterium
wolbachia
diseas
pathogenesi
bacteria
releas
dead
damag
worm
caus
inflammatori
reaction
associ
advers
reaction
chemotherapi
similar
activ
innat
inflamm
bacteria
caus
inflammatori
respons
lead
river
blind
mutualist
depend
wolbachia
use
new
approach
treatment
filariasi
antibiot
use
elimin
endosymbiont
lead
arrest
larval
embryon
develop
surviv
also
lead
eventu
death
adult
worm
suggest
bacteria
essenti
longterm
surviv
first
trial
use
doxycyclin
human
filariasi
encourag
sustain
reduct
microfilaria
longterm
steril
onchocerciasi
potent
macrofilaricid
activ
lymphat
filariasi
use
antibiot
addit
perturb
symbiot
relationship
could
also
elimin
caus
filari
diseas
first
matrix
metalloproteinas
mmp
found
critic
normal
tadpol
tail
resorpt
similar
zinccontain
proteas
sinc
identifi
central
role
physiolog
tissu
turnov
leukocyt
extravas
kda
gelatinas
kda
interstiti
collagenas
quantit
predomin
mmp
secret
monocyt
cell
pivot
antitubercul
immun
degrad
type
iv
collagen
major
compon
vascular
basement
membran
cleav
chief
structur
collagen
lung
tissu
tuberculosi
characteris
necrotis
granulomat
immun
respons
caus
tissu
destruct
poorli
understood
sinc
excess
mmp
activ
may
destruct
hypothesi
dysregul
mmp
activ
caus
tissu
injuri
tb
investig
vitro
human
monocyt
cell
infect
live
virul
mycobacterium
tuberculosi
secret
dosedepend
manner
h
concentr
increas
p
v
control
de
novo
mrna
synthesi
detect
contrast
upregul
tissu
inhibitor
matrix
metalloproteinas
timp
gene
express
secret
delay
less
strike
vivo
concentr
per
leukocyt
cerebrospin
fluid
csf
tubercul
mening
patient
higher
bacteri
viral
mening
concentr
similar
tubercul
compar
bacteri
mening
control
thu
phenotyp
activ
rel
unrestrict
develop
vitro
vivo
addit
concentrationscsf
leukocyt
level
elev
fatal
tubercul
mening
patient
sign
cerebr
damag
unconsci
confus
neurolog
deficit
p
howev
relationship
sever
system
ill
biopsi
patient
tubercul
lymphaden
next
studi
immunohistochemistri
intens
stain
found
monocyt
cell
form
center
granuloma
adjac
necrosi
minim
express
indic
unoppos
activ
sinc
granuloma
contain
mycobacteria
exist
monocytemonocyt
cytokin
network
amplifi
secret
investig
vitro
condit
media
tuberculosisinfect
primari
human
monocyt
cell
comtb
stimul
gene
express
increas
secret
monocyt
p
vs
control
antitnfantibodi
receptor
antagonist
pretreat
inhibit
secret
induc
comtb
direct
infect
p
respect
comtb
tnfindepend
stimul
dosedepend
secret
pertussi
toxin
inhibit
comtbinduc
secret
enhanc
inhibitori
effect
tnfblockad
thu
implic
chemokin
network
final
effect
antiinflammatori
cytokin
tuberculosisinfect
cell
suggest
mmp
activ
might
inadequ
suppress
convers
interferoninhibit
gene
express
secret
dosedepend
manner
conclus
tuberculosisinfect
monocyt
cell
exhibit
matrixdegrad
phenotyp
vitro
similar
phenotyp
observ
patient
activ
relat
local
tissu
injuri
found
adjac
caseou
necrosi
cytokin
network
may
amplifi
secret
monocyt
cell
within
granuloma
tnf
critic
antimycobacteri
granuloma
format
pivot
autocrin
paracrin
regul
interferon
may
protect
mmpmediat
injuri
manag
prosthet
joint
infect
requir
multidisciplinari
approach
patient
need
assess
manag
jointli
orthopaed
surgeon
specialis
complex
revis
arthroplasti
infect
specialist
plastic
surgeri
input
often
requir
care
involv
physiotherapist
occup
therapist
specialis
nurs
staff
rang
health
profession
manag
option
host
joint
microbi
factor
affect
decis
make
individu
expect
aim
clear
patient
doctor
includ
likelihood
erad
suppress
infect
reduct
pain
eventu
joint
function
option
follow
noth
attempt
suppress
antibiot
alon
may
appropri
elderli
person
comorbid
function
rel
painfre
joint
discharg
sinu
prosthesi
debrid
retent
one
twostag
revis
excis
arthroplasti
arthrodesi
amput
studi
debrid
prosthesi
retent
salvag
therapi
limit
small
number
limit
followup
period
success
rate
vari
almost
zero
earli
studi
care
select
patient
durat
symptom
debrid
appear
major
factor
determin
success
outcom
data
indic
differ
accord
infect
organ
penicillinsuscept
streptococci
coagulas
neg
staphylococci
aureu
optimum
durat
antibiot
suppress
clear
zimmerli
et
al
use
anim
model
aureu
devicerel
infect
show
antibiot
combin
includ
rifampicin
higher
rate
cure
subsequ
support
randomis
control
trial
patient
unstabl
loos
prosthesi
factor
make
salvag
impract
one
twostag
revis
consid
success
rate
vari
one
stage
procedur
two
stage
success
like
foreign
nonviabl
materi
includ
cement
remov
time
two
stage
routedur
antibiot
vari
institut
studi
advoc
aspir
biopsi
antibiot
prior
decis
reimplant
clearli
joint
still
clinic
infect
inflammatori
marker
still
high
redebrid
second
first
stage
need
prior
consid
reimplant
knee
cement
spacer
insert
two
stage
hip
mani
surgeon
leav
joint
spacer
altern
includ
cement
bead
prostalac
implant
aim
preserv
function
devic
contain
antibiot
whether
joint
retain
surgeri
especi
knee
may
requir
use
muscl
flap
adequ
soft
tissu
coverag
addit
overal
host
statu
crucial
determin
likelihood
erad
infect
use
stage
system
develop
consensu
definit
may
allow
eventu
comparison
patient
group
henc
improv
qualiti
evid
inform
clinic
decis
proven
therapi
clostridium
difficil
infect
cdi
signific
differ
respons
recurr
rate
metronidazol
vancomycin
mean
durat
symptom
margin
shorter
day
latter
symptomat
recurr
common
case
pose
therapeut
dilemma
resist
metronidazol
vancomycin
rare
describ
notabl
spain
relaps
usual
reinfect
differ
strain
switch
metronidazol
vancomycin
vice
versa
patient
symptomat
recurr
therefor
illog
first
recurr
retreat
oral
metronidazol
taperingpuls
vancomycin
week
use
noncompar
studi
similarli
combin
vancomycin
rifampicin
unproven
inconsist
suscept
data
saccharomyc
boulardii
best
studi
biotherapi
cdi
prophylaxi
treatment
efficaci
data
inconsist
risk
fungaemia
consist
anim
studi
show
heterogen
virul
boulardii
strain
biotherapi
studi
usual
open
small
true
efficaci
almost
report
regimen
unknown
lactobacillu
gg
trial
acut
diarrhoea
conflict
recent
larg
studi
show
differ
placebo
rectal
biotherapyinfus
faec
use
occasion
circumv
gastric
acid
degrad
probiot
claim
high
success
rate
undermin
impract
high
molecular
weight
polym
bind
cd
toxin
b
protect
death
coliti
hamster
well
toler
phase
human
trial
case
report
cdi
unrespons
standard
therapi
success
treat
iv
immunoglobulin
diarrhoea
prevent
hamster
bovinesourc
immunoglobulin
nonbovin
deriv
specif
antitoxin
antibodi
investig
vaccin
contain
cd
b
toxoid
safe
immunogen
healthi
volunt
induc
antitoxin
level
greater
associ
protect
clinic
studi
sinc
cook
report
infect
control
team
ict
encourag
carri
surveil
healthcareassoci
infect
hcai
two
nation
preval
survey
hcai
carri
surveil
hcai
limit
alert
organismscondit
surgic
procedur
howev
follow
nation
audit
offic
report
manag
control
hospit
acquir
infect
acut
nh
trust
england
greater
emphasi
place
need
prospect
surveil
hcai
current
ict
requir
report
mrsa
bacteraemia
outcom
elect
orthopaed
procedur
near
futur
pressur
ict
produc
surveil
data
wider
rang
alert
organismscondit
surgic
site
infect
ssi
eg
clostridium
difficil
glycopeptideresist
enterococci
caesarean
section
etc
howev
resourc
need
carri
addit
studi
yet
place
mani
part
uk
workshop
look
staff
skill
requir
ict
carri
mandatori
surveil
task
exampl
scenario
ssi
surveil
examin
detail
includ
use
core
local
dataset
methodolog
definit
mean
data
collect
one
way
forward
introduc
concept
infect
control
surveil
coordin
facilit
whole
process
person
may
requir
addit
train
basic
data
handl
analysi
skill
made
avail
member
ict
coordin
could
exist
ict
other
appropri
scientif
cleric
background
current
ict
made
consult
microbiologist
icd
icn
support
staff
icd
icn
support
number
profession
bodi
assist
one
way
anoth
basic
train
higher
degre
nevertheless
ict
still
feel
illequip
undertak
detail
surveil
hcai
discuss
number
question
need
answer
requir
teach
need
taught
teach
teach
carri
travel
medicin
rapidli
expand
subspecialti
tropic
medicin
aim
prevent
morbid
travel
rapid
increas
travel
region
intern
mani
reason
travel
tourism
commerc
migrat
subject
encompass
mani
aspect
specialti
medicin
provid
travel
advic
morbid
risk
hazard
assess
need
undertaken
defin
health
risk
may
vaccin
prevent
modifi
behavior
defin
travel
risk
requir
accur
epidemiolog
data
morbid
travel
qualiti
data
widespread
use
use
endem
diseas
risk
evalu
data
avail
incid
travel
associ
morbid
limit
poor
qualiti
morbid
associ
malaria
notifi
diseas
enabl
precis
risk
assess
made
although
compar
rel
infrequ
health
problem
morbid
associ
preexist
medic
condit
trauma
accid
import
caus
sever
travel
morbid
poorli
defin
difficult
predict
advis
risk
assess
often
therefor
base
clinic
judgment
perceiv
risk
efficaci
prophylact
often
base
studi
undertaken
endem
nativ
popul
rather
travel
identifi
risk
intervent
avail
evid
base
use
shown
provid
benefit
harm
safeti
toxic
data
prophylact
often
inconsist
base
nonrepres
group
effect
uptak
use
evid
base
intervent
poor
unpredict
risk
assess
made
travel
evid
base
protect
prophylact
measur
deriv
pertin
scientif
investig
travel
medicin
current
art
form
await
scientif
base
rabi
immunis
essenti
bat
handler
postexposur
treatment
rabi
essenti
patient
bitten
bat
patient
acut
flaccid
paralysi
presumpt
viral
enceph
ask
bitten
bat
irrespect
travel
histori
antemortem
diagnosi
bat
rabi
human
possibl
use
rtpcr
result
west
indian
popul
born
uk
thought
acquir
infect
local
vntr
type
tend
cluster
harlem
clade
commonli
repres
newli
identifi
x
clade
seen
patient
born
west
indi
group
patient
ident
miru
profil
tradit
contact
trace
previous
identifi
link
individu
although
geograph
cluster
inform
direct
epidemiolog
inquiri
may
explain
go
excess
rate
tuberculosi
within
commun
contrast
african
popul
recent
arriv
uk
diseas
result
reactiv
latent
infect
rather
local
spread
minim
cluster
vntr
profil
previou
work
identifi
attenu
mutant
contain
disrupt
lctp
gene
predict
encod
protein
ident
similar
lactat
permeas
e
coli
examin
role
lctp
gene
lactat
utilis
n
meningitidi
growth
strain
singl
carbon
sourc
compar
wildtyp
strain
two
strain
grew
equal
well
mm
glucos
lactat
permeas
mutant
defect
growth
media
lactat
sole
carbon
sourc
addit
uptak
studi
demonstr
mutant
incap
assimil
lactat
metabol
studi
show
growth
wild
type
bacterium
though
mutant
enhanc
addit
lactat
media
contain
glucos
furthermor
surviv
mutant
normal
human
sera
wildtyp
order
investig
basi
attenu
lctp
mutant
virul
assay
complement
defici
anim
perform
result
demonstr
mutant
attenu
presenc
activ
complement
pathway
result
present
mechan
underli
serum
sensit
mutant
capac
recombin
lctp
induc
protect
live
bacteri
challeng
assess
immunis
lctp
gave
consist
superior
protect
pora
surfac
express
meningococc
protein
elicit
bactericid
antibodi
work
requir
defin
immunolog
basi
protect
immun
acanthamoeba
opportunist
protozoan
parasit
caus
fatal
granulomat
amoeb
enceph
gae
eye
kerat
howev
pathogenesi
pathophysiolog
emerg
diseas
remain
incomplet
understood
aim
studi
determin
effect
acanthamoeba
host
cell
cycl
use
human
brain
microvascular
endotheli
cell
hbmec
human
corneal
epitheli
cell
hcec
two
isol
acanthamoeba
belong
genotyp
gae
isol
genotyp
kerat
isol
use
pathogen
potenti
determin
use
hbmec
hcec
respect
determin
effect
acanthamoeba
host
cell
cycl
cell
cycl
specif
gene
array
use
screen
gene
import
host
cell
cycl
regul
next
determin
effect
acanthamoeba
retinoblastoma
rb
phosphoryl
use
antiphosphorb
immunoprecipit
follow
antirb
western
blot
retinoblastoma
tumour
suppressor
protein
potent
inhibitor
cell
cycl
progress
howev
rb
function
inhibit
upon
phosphoryl
multipl
site
allow
progress
phase
acanthamoeba
isol
belong
gae
kerat
genotyp
produc
sever
cytotox
hbmec
hcec
consid
potenti
pathogen
tissu
specif
observ
indic
isol
potenti
produc
gae
andor
kerat
gene
array
analys
show
acanthamoeba
inhibit
express
gene
includ
cyclin
f
cyclin
depend
kinas
import
cell
cycl
progress
moreov
upregul
gene
express
associ
cell
cycl
arrest
observ
indic
cell
cycl
inhibit
western
blot
assay
reveal
acanthamoeba
inhibit
rb
phosphoryl
lead
cell
cycl
arrest
transit
proport
patient
flown
militari
aeromed
flight
may
potenti
expos
infecti
diseas
raf
medic
nurs
personnel
duti
take
precaut
prevent
transmiss
infect
infect
control
guidelin
use
hospit
commun
set
avail
howev
ward
feet
high
condit
cram
noisi
washbasin
run
water
one
chemic
toilet
share
two
work
environ
bare
littl
resembl
use
disinfect
strictli
forbidden
aircraft
alter
method
render
blood
spillag
safe
approach
clinic
wast
aircraft
appropri
manag
care
consid
go
back
first
principl
infect
control
exist
practic
work
environ
variou
type
aircraft
critic
analyz
result
develop
adapt
infect
control
guidelin
enabl
healthcar
personnel
prevent
transmiss
infect
within
close
confin
aircraft
environ
aeromed
transport
patient
uk
hospit
oversea
increas
involv
uk
militari
patient
also
referr
specialist
centr
use
privat
fixedw
helicopt
air
ambul
import
involv
control
infect
understand
uniqu
difficulti
type
patient
transport
appreci
even
arduou
circumst
infect
control
must
remain
prioriti
introduct
skin
infect
due
opportunist
pathogen
becom
major
problem
hivaid
nonhivaid
peopl
kenya
hiv
preval
keep
rise
world
repres
recurr
itchi
rash
mimic
variou
dermatolog
eg
cellulit
acn
etc
allergi
asthma
like
condit
result
high
use
steroid
antibiot
anti
fungal
without
success
immuno
suppress
effect
steroid
could
worsen
condit
hivaid
patient
collabor
commun
base
programm
initi
infect
control
associ
kenya
icak
ngo
take
care
sick
investig
agent
control
antibiot
steroidsantifung
high
usag
give
health
provid
effect
altern
method
itchi
condit
investig
chlorhecidin
centrimid
chlorhexidin
centrimid
benzalkonumechrorid
providon
iodin
bacteriafung
infect
isol
identifi
variou
local
avail
antisept
tri
patient
bacteri
infect
elimin
bacteria
itch
develop
normal
skin
monitor
three
year
steroidsantibiot
anti
fungal
withdrawn
result
pure
growth
exfoli
staphylococcu
aureu
isol
recurr
itchi
case
normal
skin
mix
growth
skin
normal
flora
strain
produc
exfoli
toxin
b
epidermolyt
toxin
caus
scald
skin
syndrom
itch
condit
ointment
compos
chlorhexidin
glucon
cetrimid
liquid
paraffin
petroleum
jelli
abl
control
itch
other
control
itch
elimin
exfoli
staphaureu
prevent
deform
skin
use
drastic
reduc
suffer
patient
use
steroid
antibiot
conclus
use
low
concentr
chlorhexidinecetrimid
ointment
ngo
church
health
provid
msfsbelgiumspainfr
drastic
reduc
suffer
patient
reduc
use
topic
steroid
antibiot
anti
fungal
patient
steroid
long
time
condit
look
bad
took
longer
time
heal
ointment
steroid
recommend
topic
steroid
use
hivaid
patient
number
individu
present
factori
certain
day
case
suggest
point
sourc
occur
around
august
epidem
curv
consist
number
potenti
sourc
investig
includ
wind
born
spread
neighbour
farmland
contamin
lorri
carri
hay
contamin
landfil
site
feral
cat
spread
individu
case
factori
extens
renov
work
undertaken
time
outbreak
build
materi
also
investig
possibl
sourc
outbreak
presentationpost
highlight
number
difficulti
investig
outbreak
q
fever
includ
difficult
decis
made
regard
treatment
follow
object
determin
incid
identifi
risk
factor
crosstransmiss
nosocomi
pathogen
aicu
design
set
prospect
cohort
studi
conduct
januari
april
bed
aicu
tertiari
teach
hospit
patient
method
patient
admit
h
aicu
follow
data
exposur
collect
daili
bacteri
clone
identifi
molecular
type
transmiss
event
identifi
two
patient
indistinguish
isol
treat
aicu
overlap
interv
day
apart
direct
transmiss
could
ascertain
incrimin
pathogen
isol
donor
admiss
recipi
instanc
direct
transmiss
could
determin
patient
regard
potenti
recipi
censur
current
analysi
odd
ratio
confid
interv
ci
risk
factor
transmiss
calcul
use
logist
regress
result
patient
follow
patient
day
isol
collect
type
total
episod
crosstransmiss
detect
twentyeight
patient
ascertain
recipi
give
densiti
incid
rate
first
incid
per
patient
day
median
time
event
day
immunosuppress
ci
histamin
commonli
found
biolog
tissu
low
concentr
may
associ
scombroid
poison
follow
ingest
spoil
food
contamin
enter
bacteria
often
wound
littl
import
attribut
presenc
enter
bacteria
yet
abil
organ
produc
histamin
may
clinic
signific
aim
studi
determin
whether
bacteria
isol
infect
wound
potenti
produc
histamin
vitro
cultur
enterobact
cloaca
atcc
klebsiella
pneumonia
atcc
proteu
vulgari
atcc
pseudomona
aeruginosa
atcc
staphylococcu
aureu
atcc
togeth
clinic
isol
gram
neg
bacteria
screen
product
histamin
use
four
differenti
media
supplement
histidin
bacteria
incub
minim
medium
supplement
histidin
day
cultur
supernat
collect
filter
thin
layer
chromatographi
tlc
enzym
analysi
use
test
presenc
histamin
cultur
filtrat
use
differenti
media
detect
histamin
judg
unreli
pseudomona
give
fals
posit
tlc
indic
isol
seen
produc
histamin
enzym
assay
demonstr
substanti
product
histamin
strain
morganella
morganii
ppm
histamin
lower
concentr
one
strain
morganella
morganii
enterobact
cloaca
strain
escherichia
coli
strain
klebsiella
spp
strain
histamin
detect
proteu
mirabili
strain
proteu
vulgari
strain
pseudomona
aeruginosa
strain
first
report
vitro
product
histamin
bacteria
isol
wound
possibl
histamin
product
bacteria
wound
may
lead
symptom
inflamm
may
mistaken
infect
despit
great
increas
understand
molecular
biolog
virus
associ
acut
upper
respiratori
tract
viral
infect
urti
remark
lack
knowledg
idea
urti
exhibit
season
incid
public
area
acknowledg
lack
explan
season
urti
put
forward
explan
relat
increas
crowd
suscept
person
winter
incid
urti
common
cold
influenza
exhibit
season
fluctuat
peak
respiratori
ill
winter
month
winter
season
report
wide
rang
virus
orthomyxovirus
influenza
paramyxovirus
rsv
parainfluenza
coronavirus
picornavirus
common
cold
herp
virus
adenovirus
virus
may
caus
system
ill
gain
entranc
bodi
via
upper
respiratori
tract
certain
paramyxoviru
infect
measl
mump
varicellazost
infect
chicken
pox
also
show
similar
winter
season
lower
respiratori
tract
diseas
pneumonia
may
viral
bacteri
aetiolog
also
show
similar
season
pattern
peak
ill
winter
present
discuss
idea
concern
season
urti
put
forward
new
hypothesi
discussionthat
season
exposur
cold
air
caus
increas
incid
urti
due
cool
nasal
airway
hypothesi
propos
inhal
cold
air
caus
cool
nasal
epithelium
reduct
nasal
temperatur
suffici
inhibit
local
respiratori
defenc
infect
mucociliari
clearanc
phagocyt
activ
leukocyt
case
also
made
warm
nasal
airway
consequ
nasal
congest
may
help
resolv
current
urti
introduct
adher
antiretrovir
medic
known
highli
import
achiev
viral
suppress
prevent
earli
emerg
resist
complex
regim
tablet
burden
make
adher
difficult
combin
chaotic
natur
live
hiv
patient
surpris
failur
adher
regim
common
text
messag
cheap
access
autom
text
larg
number
patient
shown
accept
use
manag
chronic
ill
howev
felt
potenti
stigma
still
surround
hiv
would
make
text
messag
hiv
unpopular
major
hiv
patient
method
questionnair
design
look
current
complianc
therapi
attitud
text
messag
offer
hiv
patient
attend
clinic
patient
ask
complet
time
clinic
visit
result
collect
anonym
result
questionnair
complet
return
mean
time
sinc
diagnosi
year
rang
patient
current
antiretrovir
treatment
found
treatment
complic
medic
state
alway
took
medic
right
time
rest
admit
sometim
take
tablet
late
occasion
forget
frequent
forget
week
take
dose
medic
patient
own
mobil
phone
indic
would
person
find
one
aspect
text
messag
servic
use
conclus
high
percentag
patient
popul
admit
poor
complianc
antiretrovir
surprisingli
larg
proport
patient
felt
text
messag
would
use
suggest
servic
develop
studi
lysostaphin
residu
antimicrobi
peptid
produc
strain
simulan
activ
mrsa
secret
simulan
ntermin
signal
peptid
tandem
repeat
remov
leav
residu
matur
lysostaphin
endopeptidas
domain
cleav
pentaglycin
crosslink
strengthen
cell
wall
aureu
produc
cell
resist
kill
lysostaphin
due
incorpor
serin
residu
pentaglycin
crosslink
lysostaphin
also
target
domain
allow
lysostaphin
bind
aureu
cell
howev
actual
receptor
molecul
identifi
carri
research
programm
aim
widen
current
limit
understand
biolog
lysostaphin
develop
rapid
purif
protocol
matur
lysostaphin
develop
fluoresc
reson
energi
transfer
fret
assay
endopeptidas
activ
identifi
conserv
residu
endopeptidas
domain
align
lysostaphin
homologu
mutat
conserv
residu
endopeptidas
domain
use
alaninescan
mutagenesi
show
loss
biolog
endopeptidas
activ
purifi
mutant
protein
inform
acquir
studi
use
help
develop
famili
novel
antimicrobi
peptid
broader
spectrum
activ
gramposit
bacteria
includ
staphylococcu
epidermidi
preempt
resist
mechan
aris
protein
use
clinic
result
patient
episod
across
seven
director
cardiolog
care
elderli
haematolog
medicin
neurolog
orthopaed
surgeri
analys
amt
input
intervent
signific
detriment
effect
either
patient
mortal
length
stay
result
stop
antibiot
identifi
patient
episod
advic
given
amt
adopt
attend
physician
case
due
new
clinic
circumst
aris
ward
round
remain
episod
rectifi
amt
follow
week
amt
ward
round
reduc
use
intraven
antimicrobi
made
direct
antimicrobi
cost
save
ward
round
day
total
cost
save
trust
rang
per
annum
depend
number
day
antibiot
chang
made
amt
preempt
similar
decis
attend
team
repres
annual
antibiot
budget
director
total
cost
save
trust
term
nurs
time
save
prevent
healthcar
associ
infect
hcai
much
greater
amt
intervent
improv
patient
care
save
larg
sum
money
increas
emerg
antibiot
resist
bacteria
major
concern
intens
care
unit
icu
patient
prospect
studi
aim
examin
antibiot
usag
bed
adult
icu
relationship
methicillin
resist
staphylococcu
aureu
mrsa
colonis
initi
month
period
patient
admit
icu
h
includ
studi
demograph
antibiot
data
collect
enhanc
mrsa
screen
two
hundr
fifteen
patient
includ
colonis
mrsa
eighti
eight
per
cent
patient
receiv
least
antibiot
mean
despit
use
primarili
surgic
prophylaxi
agent
cefuroxim
metronidazol
two
heavili
prescrib
antibiot
prescrib
extend
period
evid
base
guidelin
surgic
prophylaxi
recommend
one
dose
induct
therefor
implement
educ
programm
involv
microbiologist
surgeon
pharmacist
anaesthetist
advoc
one
surgic
prophylaxi
induct
educ
programm
second
period
data
collect
mrsa
screen
took
place
date
patient
includ
colonis
mrsa
receiv
least
antibiot
cefuroxim
metronidazol
usag
reduc
bed
day
bed
day
respect
increas
usag
tazocin
antibiot
usag
remain
rel
constant
demonstr
use
multidisciplinari
approach
possibl
reduc
post
surgic
prophylact
usag
antibiot
icu
therebi
potenti
reduc
antibiot
select
pressur
long
term
presenc
multi
resist
bacteria
object
cell
walldefici
bacteria
cwdb
associ
numer
diseas
process
howev
still
complet
understand
factor
caus
loss
cell
wall
vivo
consequ
cell
walldefici
bacteri
metabol
object
characteris
chang
antibiot
sensit
cell
wall
structur
occur
staphylococcu
aureu
cell
adopt
transient
cell
walldefici
phenotyp
method
induc
cell
walldefici
variant
aureu
media
high
osmot
potenti
presenc
subleth
level
penicillin
antibiot
sensit
profil
determin
use
disc
diffus
agar
dilut
test
sensit
cell
wall
activ
enzym
intact
cell
matrix
assist
laser
desorptionionis
time
flight
mass
spectrometri
malditof
high
perform
liquid
chromatographi
hplc
method
use
analys
cell
wall
structur
result
cwdb
resist
blactam
stain
gramneg
cell
allow
recov
wall
passag
absenc
penicillin
display
stabl
high
level
resist
blactam
antibiot
alter
sensit
sever
class
antibiot
revert
state
cell
decreas
sensit
lysi
lysostaphin
alter
signatur
malditof
revert
cell
approxim
time
mass
cell
wall
wildtyp
cell
peptidoglycan
shorter
glycan
chain
greater
number
pentaglycin
crossbridg
conclus
staphylococcu
aureu
cell
induc
transient
lose
cell
wall
presenc
penicillin
acquir
stabl
high
level
resist
blactam
alter
sensit
sever
class
antibiot
cell
wall
also
alter
like
partli
respons
chang
antibiot
sensit
profil
object
aim
studi
elucida
te
factor
associ
wide
variat
gener
practition
gp
urin
sampl
antibiot
prescrib
behaviour
patient
suspect
urinari
tract
infect
uti
method
questionnair
design
obtain
inform
n
manag
uti
compris
question
practic
demograph
eg
list
size
depriv
payment
gp
demograph
eg
age
sex
six
case
scenario
requir
detail
urin
sampl
antibiot
prescrib
behaviour
complet
qu
estionnair
receiv
gp
gener
practic
preliminari
result
twelv
percent
gp
state
polici
refer
sampl
microbiolog
analysi
laboratori
suscept
result
alway
influenc
choic
agent
empir
therapi
would
alway
request
urin
sampl
patient
repres
symptom
suggest
treatment
failur
would
alway
chang
therapi
base
laboratori
suscept
result
case
treatment
failur
conclus
high
level
variat
urin
sampl
submiss
rate
throughout
wale
indic
lack
consensu
sampl
polici
dynam
urin
sampl
antibiot
prescrib
behaviour
complex
analysi
data
present
result
introduct
polici
number
notion
day
cours
per
admiss
per
month
fell
cephalosporin
augmentin
benzyl
penicillin
use
tripl
trimethoprim
doubl
amoxycillin
use
rose
cdi
rate
fell
per
admiss
per
month
estim
save
gener
reduct
cephalosporin
use
cdi
case
avoid
month
period
conclus
introduct
narrow
spectrum
antibiot
polici
reinforc
regular
feedback
associ
reduct
broad
spectrum
antibiot
use
cephalosporin
augmentin
increas
narrow
spectrum
antibiot
prescript
benzylpenicillin
trimethoprim
amoxicillin
reduct
cdi
rate
consider
save
feedback
appear
effect
tool
optim
antibiot
use
method
antibiot
assay
request
form
two
teach
hospit
leed
collect
one
month
antibiot
dosag
schedul
time
last
dose
natur
assay
sampl
time
ident
request
staff
member
doctornurs
collect
patient
result
total
request
form
analys
inform
regard
natur
assay
provid
sampl
time
antibiot
dose
dosag
schedul
mention
time
last
dose
thu
provid
relev
clinic
data
discuss
two
third
request
inform
assay
type
peaktroughrandom
sampl
time
howev
small
proport
provid
rest
necessari
inform
time
last
dose
dosag
schedul
antibiot
dose
vital
accur
interpret
may
result
incorrect
dosag
adjust
may
potenti
detriment
patient
care
medicoleg
implic
microbiolog
clinic
staff
time
wast
tri
obtain
inform
telephon
clinic
inform
provid
microbiolog
request
form
antibiot
assay
inadequ
led
modif
request
form
educ
programm
junior
medic
staff
recommend
servic
would
also
allow
patient
maintain
lifestyl
avoid
hospit
acquir
infect
well
allow
earli
discharg
audit
patient
cellul
medic
unit
ohpat
servic
commenc
found
averag
stay
inpati
day
greater
year
old
day
servic
patient
mainli
refer
medic
admiss
unit
mau
seen
day
db
suitabl
patient
administ
dose
antibiot
mau
observ
minut
allow
home
mau
staff
arrang
appropri
investig
patient
return
infect
unit
daili
basi
parenter
antibiot
satisfactori
improv
hospit
taxi
provid
without
privat
transport
medic
review
bm
twice
weekli
manag
alter
thought
appropri
discharg
db
sent
discharg
summari
patient
gp
drug
cost
incur
medic
divis
result
patient
seen
cellul
mean
length
iv
antibiot
therapi
cellul
day
iv
ceftriaxon
antibiot
choic
unless
signific
contradict
advers
effect
patient
treat
prolong
cours
iv
antibiot
eg
malign
otiti
externa
day
case
mrsa
spinal
disciti
treat
total
day
overal
patient
day
iv
therapi
administ
estim
cost
inpati
therefor
approxim
save
earli
patient
discharg
patient
satisfact
survey
organis
questionnair
distribut
randomli
return
respond
satisfi
servic
one
dissatisfi
would
chosen
servic
need
patient
abl
maintain
normal
lifestyl
conclus
servic
appear
fulfil
goal
lead
earli
hospit
discharg
maintain
good
patient
care
earli
discharg
patient
appear
save
signific
amount
money
realiti
patient
replac
discharg
earli
howev
spill
acut
medic
patient
divis
reduc
intend
expand
servic
divis
within
trust
due
emerg
antibioticresist
woundinfect
bacteria
need
develop
new
topic
antimicrobi
agent
one
ancient
remedi
current
reconsid
honey
broadspectrum
antimicrobi
activ
demonstr
vitro
honey
effect
inhibitor
vivo
must
retain
potenc
presenc
serum
protein
yet
test
use
two
wound
pathogen
aim
investig
determin
whether
presenc
serum
protein
affect
bactericid
activ
new
zealand
manuka
honey
steril
manuka
honey
potenc
equival
wv
phenol
use
determin
minimum
inhibitori
concentr
mic
methicillinresist
staphylococcu
aureu
mrsa
nctc
pseudomona
aeruginosa
atcc
serial
dilut
nutrient
broth
oxoid
microtitr
plate
method
minimum
bactericid
concentr
mbc
determin
plate
onto
nutrient
agar
oxoid
determin
effect
serum
protein
antibacteri
activ
nutrient
broth
replac
foetal
calf
serum
fc
absenc
fc
mrsa
sensit
manuka
honey
pseud
aeruginosa
mic
valu
wv
wv
respect
mbc
respect
indic
mode
action
bactericid
presenc
fc
mic
increas
factor
approxim
respect
activ
bactericid
result
suggest
although
compon
fc
reduc
antibacteri
activ
manuka
honey
vitro
bactericid
activ
two
wound
pathogen
still
present
follow
dilut
factor
least
clinic
treatment
undilut
honey
appli
wound
exud
gener
osmot
effect
studi
suggest
honey
continu
retain
bactericid
activ
dilut
presenc
serum
protein
use
vivo
result
current
member
practic
interest
group
least
antibiot
pharmacist
around
pharmacist
respons
work
antibiot
guidelin
audit
nation
studi
day
take
place
octob
octob
ukcpa
biannual
confer
provid
network
opportun
resourc
centr
establish
provid
materi
protocol
guidelin
websit
develop
email
discuss
group
receiv
enquiri
includ
request
protocol
enquiri
drug
administr
dose
question
clinic
effect
issu
job
descript
request
antiinfect
suppli
issu
method
process
care
outcom
two
scottish
hospit
compar
prospect
two
winter
novemberapril
plan
intervent
primari
outcom
proport
patient
receiv
appropri
antibiot
british
thorac
societi
definit
within
hour
admiss
secondari
outcom
length
hospit
stay
mortal
preimplement
qualit
quantit
method
identifi
potenti
barrier
effici
deliveri
appropri
antibiot
data
use
design
target
intervent
consist
wallbas
pathway
promot
poster
implement
pack
educ
session
audit
feedback
linear
regress
use
calcul
unadjust
sever
adjust
absolut
chang
result
proport
patient
receiv
appropri
antibiot
within
hour
increas
intervent
hospit
control
hospit
unadjust
absolut
chang
p
adjust
absolut
chang
p
mostli
due
reduct
door
antibiot
time
rather
improv
antibiot
prescrib
signific
differ
secondari
outcom
intervent
hospit
main
reason
achiev
primari
outcom
postimplement
late
deliveri
antibiot
case
nonadher
evalu
period
maximum
achiev
adher
primari
outcom
estim
intervent
significantli
increas
proport
patient
receiv
appropri
antibiot
within
hour
although
evid
decreas
length
hospit
stay
mortal
background
object
aim
calcul
costeffect
educ
intervent
improv
deliveri
appropri
initi
antibiot
communityacquir
pneumonia
cap
method
analys
perform
hospit
perspect
cost
calcul
use
price
direct
cost
healthcar
divid
cost
hospitalis
initi
antibiot
therapi
outlier
patient
length
stay
day
admit
high
depend
exclud
unadjust
adjust
differ
mean
cost
pre
postimplement
calcul
use
linear
regress
significantli
differ
net
cost
ad
intervent
cost
link
primari
outcom
proport
patient
receiv
appropri
antibiot
hour
admiss
result
postintervent
period
ci
addit
patient
receiv
appropri
antibiot
within
hour
preintervent
period
cost
hospitalis
initi
antibiot
therapi
per
patient
respect
postintervent
cost
increas
adjust
differ
p
adjust
differ
p
adjust
total
net
direct
health
care
cost
total
project
cost
includ
develop
implement
evalu
train
scenario
cost
hospit
adapt
implement
perform
limit
evalu
estim
scenario
b
cost
hospit
adapt
implement
intervent
estim
scenario
c
postimplement
evalu
period
cost
per
addit
patient
receiv
appropri
antibiot
within
hour
scenario
b
c
intervent
result
improv
care
consider
cost
cost
would
decreas
notabl
electron
caserecord
avail
costeffect
ratio
also
becom
favour
time
background
antibiot
resist
present
major
challeng
local
nation
intern
guidanc
suggest
promot
prudent
prescrib
antibiot
particularli
newer
agent
use
altern
linezolid
recent
launch
uk
activ
gram
posit
bacteria
includ
mrsa
vancomycinresist
enterococci
approv
use
trust
follow
microbiolog
infecti
diseas
id
approv
howev
juli
treat
patient
linezolid
month
expenditur
increas
isol
resist
organ
object
introduc
system
ensur
linezolid
use
appropri
assess
impact
remov
linezolid
ward
obtain
via
pharmaci
adapt
system
mandatori
order
form
uk
use
requir
prescrib
complet
detail
patient
infect
prescrib
previou
agent
microbiologyid
approv
section
must
complet
dispens
form
fax
prescrib
back
pharmaci
fill
pharmacist
via
telephon
system
also
appli
even
weekend
compar
linezolid
usag
introduct
result
usag
decreas
averag
patient
per
month
first
month
next
month
comparison
audit
form
pharmaci
dispens
data
show
form
complet
patient
complet
audit
data
patient
includ
clinic
specialti
site
infect
organ
evid
microbiologyid
approv
patient
conclus
introduct
mandatori
order
form
curtail
growth
linezolid
use
provid
system
ongo
monitor
feedback
usag
pattern
extend
system
antiinfect
method
effect
four
compar
antibiot
vancomycin
teicoplanin
linezolid
moxifloxacin
assess
bactericid
activ
staphylococc
biofilm
experi
carri
use
sorbarod
biofilm
strain
test
includ
methicillinsuscept
resist
strain
stahphylococcu
aureu
coagulaseneg
staphylococci
well
gisa
strain
bacteria
expos
antibiot
exponenti
decreas
concentr
repres
parenter
administr
also
constant
concentr
repres
iv
infus
concentr
use
correspond
peak
serum
level
rate
drug
concentr
decreas
correspond
elimin
halfliv
drug
test
produc
reduct
number
cell
elut
biofilm
method
exposur
overal
constant
concentr
method
antibiot
exposur
effect
exponenti
decreas
concentr
exposur
reduc
number
bacteria
elut
staphylococc
biofilm
method
exposur
effect
establish
glycopeptid
vancomycin
teicoplanin
log
reduct
end
experi
vs
log
reduct
respect
exponenti
decreas
concentr
method
conclus
effici
agent
among
test
nongisa
gisa
strain
method
exposur
conclud
appear
promis
antibiot
treatment
multidrug
resist
staphylococc
biofilm
associ
infect
pyomyos
subacut
bacteri
infect
skelet
muscl
report
case
pyomyos
right
thigh
iliopsoa
muscl
intraven
drug
user
present
review
literatur
reveal
report
case
commun
acquir
methicillinresist
staphylococcu
aureu
mrsa
pyomyos
patient
present
two
week
histori
pain
swell
right
thigh
although
initi
diagnosi
deep
vein
thrombosi
consid
laboratori
imag
studi
suggest
right
thigh
iliopsoa
pyomyos
diagnosi
pyomyos
confirm
oper
incis
drainag
washout
undertaken
patient
worsen
convent
treatment
benzylpenicillin
flucloxacillin
requir
incis
drainag
mrsa
streptococcu
pyogen
cultur
necrot
materi
excis
thigh
initi
oper
antibiot
regimen
convert
includ
glycopeptid
follow
debrid
patient
slowli
improv
review
literatur
undertaken
use
search
medlin
embas
search
found
number
hospit
acquir
case
mrsa
pyomyos
three
report
commun
acquir
mrsa
pyomyos
worldwid
case
report
uk
case
report
show
convent
antibiot
pyomyos
may
effect
even
patient
commun
may
necessari
consid
glycopeptid
vancomycin
initi
treatment
regimen
pyomyos
certain
subset
patient
intraven
drug
user
convert
convent
therapi
cultur
fail
grow
resist
organ
object
work
develop
pcr
tuberculosi
use
primer
insert
element
although
primer
condit
previous
publish
pcr
reaction
found
lack
reproduc
display
fold
variat
sensit
condit
chang
differ
thermost
taq
polymeras
use
faststart
taq
polymeras
roch
signific
contamin
problem
occur
optimalis
complet
control
use
enzym
uracil
dna
glycosylas
ung
indic
carryov
contamin
rather
cross
contamin
sensit
pcr
reaction
use
dna
type
strain
tuberculosi
fentogram
g
target
sensit
well
specif
pcr
reaction
confirm
southern
blot
intern
primer
design
use
make
radiolabel
probe
southern
blot
would
suitabl
use
develop
nest
pcr
disciti
inflammatori
process
intervertebr
disc
usual
involv
vertebr
end
plate
may
extend
adjac
tissu
applic
magnet
reson
imag
diagnosi
disciti
led
increas
awar
cultur
disc
aspir
highlight
bacteri
aetiolog
retrospect
studi
clinic
present
investig
antibiot
treatment
disciti
carri
august
septemb
review
clinic
note
laboratori
record
taunton
somerset
hospit
twenti
four
adult
patient
identifi
year
back
pain
commonest
present
symptom
alter
muscl
weak
sensat
observ
patient
respect
predispos
condit
present
patient
includ
previou
bacteraemia
haematolog
malign
diabet
immunosuppress
recent
surgeri
c
reactiv
protein
white
cell
count
rais
patient
respect
microbiolog
investig
carri
patient
includ
cultur
blood
intervertebr
disc
aspir
urin
occasion
staphylococc
serolog
staphylococcu
aureu
isol
eleven
patient
singl
isol
proteu
vulgari
pseudomona
aeruginosa
candida
glabrata
also
grown
flucloxacillin
fusid
acid
common
antibiot
regim
use
treatment
regim
guid
suscept
organ
isol
magnet
reson
sensit
specif
method
imag
detect
disciti
microbiolog
investig
patient
order
isol
caus
organ
critic
success
time
outcom
treatment
conclud
patient
localis
spinal
pain
presenc
risk
factor
particularli
accompani
fever
rais
crp
must
investig
disciti
magnet
reson
imag
fusobacterium
necrophorum
associ
seriou
infect
usual
previous
healthi
young
peopl
caus
condit
known
lemierr
diseas
also
associ
seriou
infect
anim
caus
condit
known
necrobacillosi
organ
split
two
subspeci
known
f
necrophorum
ss
necrophorum
f
necrophrum
ss
funduliform
sometim
refer
biotyp
b
respect
literatur
state
biotyp
mostli
associ
diseas
anim
biotyp
b
human
infect
although
largescal
investig
human
isol
perform
substanti
anaerob
refer
laboratori
larg
collect
isol
f
necrophorum
refer
identif
case
human
infect
howev
subtyp
routin
perform
present
paper
describ
subtyp
investig
isol
f
necrophorum
human
infect
base
chickcel
agglutin
alkalin
phosphatas
preliminari
pcrrflp
profil
appear
differenti
two
subspeci
provision
result
base
product
alkalin
phosphatas
indic
unexpectedli
belong
subspeci
necrophorum
biotyp
result
confirmatori
test
present
introduct
present
sever
drugresist
commun
acquir
infect
caus
global
concern
includ
emerg
entero
pathogen
toxic
e
coli
shigella
organ
transmit
untreat
water
unhygen
prepar
food
studi
go
year
kenya
show
breakdown
public
health
facil
use
untreat
water
poverti
result
unhygien
hous
misus
antibiot
tri
treat
enter
pathogen
thu
increas
mortal
morbid
especi
hivaid
peopl
show
although
current
enterotoxigen
e
coli
sensit
new
introduc
quinolon
cephalosporion
drug
kill
bacteria
effect
alreadi
produc
toxin
patient
gut
call
new
approach
control
spread
manag
toxinproduc
food
poison
agent
neutral
toxin
produc
agent
abl
neutral
toxin
combin
effect
antibiot
method
food
poison
agent
investig
outbreak
kenya
sensit
done
toxin
produc
investig
model
transmiss
studi
health
provid
advis
drug
use
manag
ie
antibiot
toxin
neutral
agent
attapulgit
without
result
new
food
poison
toxin
produc
agent
discov
ad
convent
one
thu
make
manag
food
poison
expens
difficult
organ
continu
develop
resist
new
drug
plasmid
resist
factor
food
poison
due
toxigen
agent
e
coli
respond
better
antibiot
combin
activ
attapulgit
magnesium
aluminum
silic
chemic
high
absorb
power
neutral
toxin
produc
treat
antibiot
continu
stomachach
constip
recommend
studi
show
antibiot
attapulgit
one
cheapest
drug
food
poison
due
food
water
born
toxinproduc
agent
eat
freshli
prepar
food
recommend
hivaid
nonhivaid
peopl
raw
food
salad
safe
lowresourc
countri
treat
water
point
use
use
sodium
hypochlorit
best
solut
control
food
poison
diseas
lowresourc
countri
awar
evidencebas
guidelin
durat
iv
antibiot
bone
joint
infect
experi
use
initi
iv
follow
oral
po
antibiot
suspect
approach
manag
use
wide
uk
recommend
use
po
antibiot
medic
microbiologist
countri
knowledg
treatment
guidelin
respect
orthopaed
infect
investig
determin
whether
week
iv
therapi
still
consid
standard
practic
orthopaed
infect
method
questionnair
antibiot
recommend
defin
orthopaed
infect
knowledg
publish
guidelin
avail
local
ohpat
sent
microbiologist
british
isl
ireland
result
questionnair
return
oral
antibiot
recommend
treatment
mssa
osteomyel
septic
arthriti
respond
recommend
iv
oral
switch
mrsa
osteomyel
replac
prosthet
knee
infect
microbiologist
respond
unawar
evidencebas
guidelin
durat
iv
antibiot
orthopaed
infect
access
ohpat
local
conclus
despit
tradit
use
week
parenter
therapi
bone
joint
infect
lack
evidencebas
oral
antibiot
commonli
recommend
medic
microbiologist
manag
infect
countri
earli
oral
switch
therapi
may
one
reason
ohpat
becom
wide
establish
uk
usa
faecal
specimen
yield
mott
posit
cultur
tuberculosi
pertain
case
pulmonari
tuberculosi
male
mean
age
case
detect
faecal
mycobacteri
cultur
sd
year
case
tuberculosi
detect
faecal
cultur
tuberculosi
grew
either
faec
prior
detect
respiratori
specimen
identifi
patient
imposs
obtain
respiratori
specimen
conclus
cultur
faecal
specimen
mycobacteria
noninvas
provid
microbiolog
confirm
infect
tuberculosi
antibiot
sensit
profil
guid
decis
regard
choic
durat
therapi
patient
suspect
pulmonari
tuberculosi
respiratori
specimen
unobtain
result
three
case
evid
ie
echocardiogram
group
g
streptococcu
isol
blood
cultur
one
case
two
case
blood
cultur
taken
antibiot
commenc
streptococcu
milleri
isol
pu
drain
brain
abscess
one
case
requir
multidisciplinari
input
optimis
manag
three
case
respond
antibiot
treatment
conclus
need
clinician
disciplin
appreci
vigil
variou
clinic
manifest
ie
correct
manag
essenti
favour
outcom
microbiologist
play
key
role
ensur
appropri
investig
prompt
diagnosi
multidisciplinari
approach
introduct
oncedaili
gentamicin
mgkg
combin
piperacillintazobactam
establish
regimen
treatment
pseudomon
infect
critic
ill
also
known
due
variabl
pharmacokinet
septic
patient
wide
dose
rang
gentamicin
achiev
appropri
serum
level
review
use
intens
care
unit
icu
method
exclus
criteria
age
year
serum
creatinin
mmoll
recent
nephrotox
chemotherapi
serum
trough
level
measur
hour
first
dose
altern
day
serum
level
mgl
gentamicin
discontinu
level
mgl
dose
halv
level
mgl
gentamicin
assay
laboratori
databas
review
patient
note
retrospect
analys
identifi
risk
factor
includ
age
inotrop
depend
renal
support
chronic
renal
diseas
nephrotox
drug
result
gentamicin
assay
perform
patient
level
satisfactori
mgl
rang
mgl
mgl
level
mgl
patient
receiv
inotrop
patient
receiv
intraven
frusemid
group
two
patient
chronic
renal
diseas
two
receiv
haemoflitr
significantli
rais
level
patient
one
risk
factor
differ
mean
age
patient
normal
gentamicin
level
year
rais
level
year
conclus
oncedaili
gentamicin
therapi
safe
critic
ill
patient
although
trough
level
significantli
rais
compar
previou
review
neutropaen
patient
risk
factor
elev
level
common
icu
close
individu
monitor
gentamicin
therapi
alway
indic
detail
analysi
mrsa
isol
highlight
number
unusu
trait
notabl
strain
display
distinct
antibiogram
resist
methicillin
fusid
acid
erythromycin
suscept
ciprofloxacin
lyse
broad
rang
phage
genotyp
analys
reveal
presenc
gene
encod
enterotoxin
h
strain
classifi
sccmec
type
agr
group
preliminari
mlst
data
suggest
sequenc
type
addit
sma
profil
pfge
show
isol
indistinguish
data
suggest
strain
repres
singl
clone
appear
predilect
idu
quit
distinct
current
preval
healthcareassoci
mrsa
uk
geograph
tempor
distribut
strain
year
suggest
drug
contamin
problem
find
indic
need
systemat
investig
natur
histori
pathogen
epidemiolog
clone
describ
investig
treatment
famili
glasgow
recurr
skin
abscess
march
initi
patient
year
old
girl
present
month
histori
recurr
skin
abscess
affect
trunk
limb
face
swab
taken
abscess
grew
aureu
sensit
flucloxacillin
patient
treat
numer
cours
antibiot
abscess
recur
complet
cours
time
five
famili
household
member
also
found
aureu
associ
recurr
skin
abscess
puls
field
gel
electrophoresi
pfge
sampl
isol
indistinguish
strain
also
found
contain
pantonvalentin
leukocidin
pvl
gene
famili
member
treat
bodi
wash
aquasept
liquid
mupirocin
nasal
decolonis
twice
daili
chlohexidin
spray
erad
oral
colonis
household
also
profession
clean
use
trigen
floor
hard
surfac
toilet
window
ledg
door
handl
underwear
bed
machin
wash
daili
basi
year
sinc
intervent
report
staphylococc
infect
aggress
manag
patient
reduct
environment
load
aureu
break
cycl
recurr
infect
strain
also
found
contain
pvl
gene
associ
recurr
furunculosi
patient
organ
usual
consid
skin
oral
commens
also
identifi
particularli
coagulas
neg
staphylococci
diphtheroid
speci
may
reflect
blood
cultur
contamin
unhygien
inject
techniqu
drug
use
paraphernalia
spectrum
organ
identifi
bacteraem
idu
northeast
glasgow
similar
seen
american
citi
interestingli
bacteraem
idu
older
gener
idu
popul
northeast
glasgow
suggest
associ
durat
drug
use
sever
septic
complic
increas
risk
bacteraem
complic
may
explain
resort
skin
muscl
pop
venou
access
lost
teicoplanin
bactericid
glycopeptid
play
import
role
gramposit
bacteri
infect
monitor
teicoplanin
level
current
routin
practic
due
varieti
reason
uk
recommend
suggest
therapeut
monitor
may
optimis
dose
serum
trough
level
less
mgl
recent
sever
studi
reveal
substanti
proport
studi
popul
concentr
less
mgl
standard
dosag
rais
concern
patient
may
properli
treat
howev
argu
vast
major
patient
concentr
mic
mgl
aim
studi
examin
differ
clinic
respons
patient
serum
trough
level
mgl
level
mgl
clinic
respons
assess
chang
bodi
temperatur
wcc
crp
around
five
day
start
administr
far
patient
studi
patient
serum
trough
level
less
mgl
includ
data
analysi
group
level
mgl
patient
group
b
level
greater
mgl
patient
mean
concentr
group
mgl
standard
deviat
wherea
mean
mgl
respect
group
b
signific
differ
observ
wcc
chang
two
group
group
group
b
show
reduct
wcc
wherea
signific
chang
notic
crp
group
whole
differ
clinic
respons
patient
serum
level
mgl
mgl
studi
go
patient
longer
observ
time
arriv
conclus
year
old
woman
underw
uncompl
lumbosacr
discectomi
five
day
later
admit
sever
back
pain
xray
unhelp
presumpt
diagnosi
postop
wound
infect
made
intraven
iv
vancomycin
oral
rifampicin
start
empir
clinic
improv
two
week
transfer
institut
present
maximum
temperatur
erythrocyt
sediment
rate
esr
mmhr
c
reactiv
protein
crp
mgl
reoper
pu
fragment
disc
remov
five
five
intraop
specimen
posit
enterobact
cultur
diagnosi
enterobact
osteomyel
made
vancomycin
rifampicin
discontinu
receiv
two
week
amikacin
g
daili
plu
meropenem
g
three
time
daili
dramat
improv
clinic
peripher
insert
central
cathet
picc
line
insert
patient
discharg
receiv
ertapenem
g
iv
daili
four
week
complet
intraven
therapi
esr
mmhr
crp
mgl
current
receiv
six
week
oral
ciprofloxacin
mg
twice
daili
conclus
ertapenem
daili
infus
attract
option
outpati
home
iv
antibiot
servic
easili
deliv
exampl
exist
support
use
bone
infect
howev
method
prospect
clinic
studi
collect
data
case
moe
year
determin
clinic
featur
imag
find
microbiolog
respons
therapi
complic
result
patient
male
femal
age
rang
year
seen
clinic
featur
includ
ear
pain
cranial
nerv
palsi
dysphagia
mening
predispos
factor
includ
steroid
diabet
otiti
externa
ear
syring
ent
surgeri
present
case
inflammatori
marker
rais
patient
mri
scan
reveal
inflammatori
mass
abscess
osteomyel
occur
skull
base
cervic
spine
patient
delay
diagnosi
common
patient
respond
cours
least
week
dual
antipseudomon
antibiot
one
patient
mening
need
vp
shunt
hydrocephalu
conclus
moe
seriou
condit
delay
diagnosi
use
inadequ
antibiot
therapi
common
allow
develop
complic
cranial
nerv
palsi
osteiti
diagnosi
care
consid
patient
ear
pain
rais
inflammatori
marker
histori
predispos
factor
sought
mri
scan
subsequ
microbiolog
sampl
inflammatori
mass
undertaken
treatment
least
week
combin
antipseudomon
antibiot
requir
effect
cure
neurosurg
intervent
may
requir
complic
background
resurg
seriou
invas
group
streptococc
infect
amongst
inject
drug
user
brighton
aim
studi
undertaken
see
whether
differ
toxin
genotyp
group
streptococci
ga
blood
cultur
isol
inject
drug
user
idu
compar
similar
blood
cultur
isol
local
commun
brighton
method
ga
isol
grown
overnight
toddhewitt
broth
cell
spun
genom
dna
extract
isol
toxin
genotyp
pcr
specif
primer
toxin
gene
amplifi
includ
encod
streptococc
superantigen
streptococc
pyrogen
exotoxin
spea
streptococc
pyrogen
exotoxin
c
spec
streptococc
mitogenc
exotoxin
z
smez
isol
also
check
presenc
mfdnase
b
gene
also
known
spef
serotypeemm
type
result
control
ga
isol
commun
spea
posit
compar
idu
ga
isol
data
toxin
gene
includ
spec
smez
present
expect
ga
idu
control
possess
mf
gene
idu
isol
type
reveal
higher
number
ga
type
one
case
new
emm
type
found
conclus
ga
isol
idu
blood
cultur
distinct
isol
nonidu
popul
addit
recent
report
preval
higher
type
idu
carriag
spea
gene
commun
ga
isol
much
greater
isol
idu
aim
investig
microbiolog
epidemiolog
cluster
mrsa
bacteraemia
local
ivdu
popul
method
sensit
test
aureu
isol
perform
bsac
recommend
mrsa
isol
type
puls
field
gel
electrophoresi
pfge
molecular
work
carri
determin
staphylococc
chromosom
cassett
type
sccmec
case
note
review
perform
ascertain
epidemiolog
differ
ivdu
mrsa
mssa
report
experi
debrid
accompani
close
doubl
lumen
suction
irrig
system
modifi
describ
lautenbach
insert
intraoss
object
primari
aim
current
studi
identifi
bacteri
speci
detect
within
oscc
tumour
tissu
combin
cultur
molecular
techniqu
method
time
surgeri
cm
specimen
collect
asept
techniqu
deep
within
tumour
surfac
decontamin
tissu
specimen
perform
immers
betadin
specimen
subsequ
bisect
half
asept
macer
resuspend
pb
cultur
aerob
anaerob
condit
nonselect
media
remaind
specimen
digest
proteinas
k
subject
dna
extract
analys
nest
pcrdgge
techniqu
use
univers
primer
bacteria
detect
method
identifi
rdna
sequenc
analysi
result
divers
bacteri
speci
includ
gram
posit
neg
facult
anaerob
speci
isol
identifi
use
method
pcrdgge
approach
detect
presenc
addit
speci
isol
cultur
neg
result
cultur
pcr
analysi
wash
tumour
specimen
signifi
surfac
decontamin
success
bacteria
detect
within
tumour
tissu
conclus
divers
bacteri
group
isol
within
tissu
oral
squamou
carcinoma
cultur
molecular
mean
signific
bacteria
within
tumour
tissu
warrant
studi
result
total
set
blood
cultur
receiv
laboratori
liver
unit
studi
period
posit
differ
organ
isol
frequent
isol
coagulaseneg
staphylococci
gramneg
bacilli
next
common
half
isol
deem
clinic
signific
sourc
signific
organ
intraabdomin
catheterrel
wound
infect
gramneg
isol
consid
clinic
signific
nine
isol
resist
cefuroxim
conclus
expect
cohort
patient
liver
diseas
common
sourc
signific
blood
cultur
isol
intraabdomin
catheterrel
particular
concern
twothird
gramneg
organ
resist
cefuroxim
routin
prescrib
patient
clinic
detail
review
view
possibl
chang
antibiot
polici
unit
isol
escherichia
coli
produc
extendedspectrumlactamas
identifi
clinic
specimen
three
patient
resid
surgic
ward
fourth
isol
obtain
anoth
patient
itu
differ
floor
hospit
serotyp
antibiogram
pulsefield
gel
electrophoresi
follow
digest
restrict
endonucleas
xbal
perform
isol
indistinguish
three
type
techniqu
initi
appear
connect
three
patient
surgic
ward
fourth
never
admit
howev
detail
review
four
patient
reveal
patient
briefli
adjac
bed
patient
whilst
itu
postop
care
spread
multiresist
organ
facilit
practic
patient
movement
ward
ward
essenti
limit
unnecessari
movement
patient
colon
infect
multiresist
bacteria
order
effect
control
nosocomi
transmiss
product
extendedspectrum
betalactamas
esbl
enterobacteriacea
pose
therapeut
problem
organ
associ
sever
ill
pneumonia
mening
compromis
use
third
gener
cephalosporin
empir
first
line
therapi
condit
aim
studi
evalu
well
routin
sensit
test
predict
esbl
product
e
coli
klebsiella
spp
blood
cultur
test
esbl
product
use
doubl
disc
synergi
test
combin
disk
test
routin
sensit
test
clinic
laboratori
breakpoint
method
includ
ceftazidim
repres
third
gener
cephalosporin
overal
proport
esblproduc
e
coli
klebsiella
spp
respect
routin
test
detect
esblproduc
enterobacteriacea
sensit
specif
total
isol
taken
medic
intens
environ
esblposit
isol
came
environ
esblproduc
pathogen
may
appear
suscept
third
gener
cephalosporin
vitro
whilst
resist
vivo
result
confirm
organ
resist
screen
cephalosporin
assum
esblproduc
confirmatori
test
undertaken
esbl
detect
highrisk
patient
locat
must
activ
sought
opportunist
glean
may
involv
includ
two
screen
two
differ
third
gener
cephalosporin
routin
sensit
test
test
specif
esbl
isol
highrisk
unitspati
method
data
patient
admiss
collect
hospit
comput
record
infecti
diseas
notif
form
retrospect
survey
hospit
staff
carri
use
facetofac
structur
questionnair
conclus
hospit
staff
account
case
gastroenter
unit
oper
effect
hospit
put
risk
outbreak
studi
chang
work
practic
initi
prevent
control
similar
outbreak
futur
method
data
patient
admiss
collect
hospit
comput
record
infecti
diseas
notif
form
earli
stage
outbreak
patient
ask
exposur
specif
risk
factor
result
one
month
period
hospit
present
refer
physician
due
gastroenter
requir
hospit
admiss
rate
admiss
gastroenter
initi
high
reduc
time
averag
length
stay
gastroenter
patient
day
led
bedday
occupi
bed
occup
rate
hospit
reach
hospit
staff
account
gastroenter
case
epidem
curv
gastroenter
case
show
rapid
increas
follow
biphas
reduct
wherea
hospit
staff
case
show
rapid
decreas
case
amongst
nonhospit
staff
came
local
unit
risk
factor
gastroenter
amongst
patient
includ
affect
colleagu
eat
fresh
fruit
use
centralis
cater
poor
handwash
facil
eat
pasteuris
yoghurt
unit
case
higher
averag
exposur
risk
factor
stool
investig
reveal
presenc
calicivirus
conclus
gastroenter
major
caus
morbid
oper
may
impact
oper
effect
unit
affect
studi
chang
work
practic
initi
prevent
control
similar
outbreak
futur
twelv
patient
infect
b
cepacia
complex
eight
bcc
genomovar
ii
one
genomovar
iiib
one
genomovar
iv
two
type
unknown
twentyseven
patient
stenotrophomona
maltophilia
patient
alcaligien
spp
isol
sputum
respect
figur
compat
multicentr
studi
unit
state
note
one
patient
sputum
cultur
posit
pandorea
pulmonicola
recent
describ
non
ferment
gram
neg
rod
possibl
transmiss
pathogen
potenti
studi
period
two
patient
cultur
posit
three
occas
atyp
mycobacteria
one
mycobacterium
abscessu
avium
intracellular
howev
number
patient
mycobacteri
sputum
cultur
perform
unknown
scedosporium
apiospermum
unusu
fungal
isol
amphoteracin
resist
isol
two
patient
organ
may
implic
lung
transplant
ongo
surveil
lower
respiratori
tract
infect
cystic
fibrosi
patient
essenti
p
aeruginosa
remain
one
lead
pathogen
cystic
fibrosi
problem
emerg
antibiot
resist
outbreak
infect
organ
emphasis
import
surveil
access
molecular
epidemiolog
type
detect
control
outbreak
develop
use
reliabl
reproduc
sensit
test
method
includ
synergi
test
guid
treatment
p
definit
use
two
resist
strain
allow
possibl
faulti
disc
transcript
error
object
uniform
standardis
method
advoc
improv
standard
recoveri
organ
five
year
laboratori
quarterli
measur
review
recoveri
rate
pathogen
use
agre
standard
exclus
criteria
conduct
assess
detect
improv
adopt
standard
method
whether
signific
chang
denomin
base
recoveri
rate
suggest
chang
epidemiolog
method
laboratori
comput
retrospect
interrog
isol
sometim
patient
basi
detect
chang
recoveri
rate
correl
adopt
time
phl
standard
method
regress
line
trend
time
plot
compar
chang
assess
numer
result
reduct
preval
salmonella
highli
correl
quantit
similar
laboratori
staph
aureu
campyobact
isol
rate
similar
laboratori
stabl
serial
increas
preval
mrsa
proport
aureu
detect
differ
time
laboratori
method
problem
clostridium
difficil
haemophilu
influenza
detect
c
difficil
methodolog
standardis
laboratori
h
influenza
isol
rate
chang
rose
one
laboratori
increas
sensit
associ
decreas
dilut
interlaboratori
intralaboratori
variat
detect
anaerob
continu
adopt
standard
method
continu
interlaboratori
stabl
variat
isol
rate
haemolyt
streptococci
streptococcu
pneumonia
cryptosporidiosi
giardiasi
declin
laboratori
except
chang
sensit
haemophilu
influenza
evid
standardis
improv
organ
recoveri
rate
laboratori
year
howev
denomin
base
data
reveal
difficulti
method
unexplain
stabl
differ
laboratori
organ
recoveri
rate
denomin
base
data
suitabl
use
compar
intern
qualiti
control
assess
also
detect
chang
organ
epidemiolog
purpos
studi
estim
extent
methicillinsensit
aureu
mssa
inhibit
colonis
mrsa
method
mrsa
mssa
isol
routin
screen
nasal
swab
collect
six
month
period
identifi
use
standard
laboratori
method
differ
observ
number
patient
swab
cocolonis
compar
expect
assum
interfer
mssa
mrsa
result
result
routin
patient
screen
swab
avail
analysi
signific
trend
carriag
mrsa
increas
age
male
compar
femal
one
hundr
fifteen
patient
swab
colon
mssa
alon
mrsa
alon
mrsa
mssa
isol
four
nasal
swab
significantli
less
expect
potenti
impact
differ
rate
colonis
mssa
epidemiolog
mrsa
illustr
use
mathemat
model
aim
conduct
analysi
adher
biofilm
form
capac
five
epidermidi
isol
associ
neurosurg
devicerel
infect
method
isol
screen
presenc
ica
operon
pcr
assay
use
microtitr
plate
assay
biofilmform
capac
evalu
standard
laboratori
stressinduc
condit
growth
nacl
etoh
cell
surfac
hydrophob
zeta
potenti
adher
isol
silicon
disc
logarimeth
stationari
phase
measur
condit
result
three
isol
contain
ica
operon
two
isol
one
ica
posit
remain
biofilmneg
condit
remain
three
isol
one
weakli
biofilm
form
standard
laboratori
condit
could
induc
form
strong
biofilm
stressinduc
condit
induct
biofilm
stressinduc
condit
associ
increas
cell
surfac
hydrophob
surfac
charg
individu
isol
standard
stressinduc
condit
correspond
specif
adher
biofilmform
characterist
isol
contain
ica
operon
show
tenfold
increas
adher
silicon
disc
variat
adher
stressinduc
condit
necessarili
correl
biofilm
format
condit
presenc
ica
operon
associ
increas
adher
biomateri
necessarili
suffici
biofilm
format
cell
surfac
hydrophob
may
play
role
initi
adher
understand
surfac
properti
adher
characterist
staphylococci
may
assist
develop
biomateri
resist
bacteri
adhes
nine
month
period
eightbed
icu
patient
investig
suspect
crbsi
one
posit
blood
cultur
central
peripher
cultur
receiv
simultan
posit
dtp
hour
dtp
hour
two
howev
altern
sourc
bacteraemia
could
found
one
bacteraemia
persist
follow
line
remov
three
month
period
calcul
number
patient
cathet
day
number
patient
day
although
cathet
day
consist
lower
patient
day
linear
relationship
two
data
suggest
pair
central
peripher
cultur
assess
dtp
may
help
diagnosi
crbsi
icu
set
although
alway
exclud
sourc
calcul
infect
rate
cathet
day
provid
accur
denomin
patient
day
may
accept
simpler
altern
mrsa
import
caus
bacteraemia
recent
surveil
data
england
shown
staphylococcu
aureu
sa
bacteraemia
caus
mrsa
major
implic
choic
antibiot
therapi
result
identif
suscept
test
blood
cultur
take
two
day
look
use
rapid
method
detect
mrsa
blood
cultur
time
detect
posit
cultur
use
autom
blood
cultur
detect
system
impact
might
choic
antibiot
therapi
retrospect
studi
posit
blood
cultur
use
evalu
roch
light
cycler
meca
staphylococc
pcr
blood
cultur
previous
demonstr
posit
recultur
addit
aliquot
cultur
broth
extract
use
magnapur
kit
pcr
reaction
perform
sampl
contain
coagulas
neg
staphylococci
cn
alon
gave
compat
pcr
result
either
neg
show
inhibit
sampl
contain
mrsa
alon
gave
compat
pcr
result
case
cultur
mix
mrsa
cn
one
gave
equivoc
result
one
posit
cn
meca
posit
overal
sensit
specif
detect
mrsa
retrospect
analysi
staphylococc
bacteraemia
detail
collect
clinic
advic
given
time
initi
cultur
posit
compar
appropri
advic
light
identif
sensit
result
correct
manag
advis
time
initi
posit
unnecessari
antibiot
recommend
case
appropri
antibiot
recommend
use
method
rapid
detect
sensit
specif
give
result
within
hour
could
significantli
impact
clinic
practic
guid
appropri
manag
could
also
decreas
laboratori
workload
identifi
insignific
isol
cultur
occur
bacteraemia
patient
nontunnel
central
venou
cathet
cvc
measur
use
denomin
patient
cathet
day
computer
code
system
use
identifi
catheteris
patient
method
computer
procedur
code
system
identifi
patient
cvc
insert
six
month
period
patient
note
review
bacteraemia
identifi
laboratori
databas
cvc
use
less
hour
includ
measur
rate
infect
result
cvc
insert
place
emerg
half
line
place
fewer
day
mean
durat
day
cvc
insert
critic
area
insert
gener
ward
theatr
line
reason
remov
document
remov
due
infect
sum
life
span
cvc
day
ten
episod
bacteraemia
identifi
overal
cvc
associ
bacteraemia
rate
cathet
day
episod
organ
also
grown
line
tip
line
tip
submit
cultur
yield
signific
growth
bacteria
conclus
rate
bacteraemia
higher
mani
publish
surveil
system
uk
data
hospit
acquir
bacteraemia
exist
record
rate
per
cathet
day
method
use
allow
calcul
use
rate
oppos
number
cathet
infect
rate
measur
total
bacteraemia
primari
line
associ
infect
computer
code
system
fail
record
line
insert
miss
mani
critic
care
episod
retrospect
review
time
consum
like
result
accur
bacteraemia
rate
measur
rate
suggest
local
antimicrobi
impregn
line
would
cost
effect
method
horizont
surfac
sampl
contact
plate
air
sampl
surfac
air
sampler
sa
settl
plate
twice
week
four
week
room
patient
isol
mrsa
hospit
mrsa
endem
plate
incub
hour
isol
identifi
antibiot
suscept
test
perform
use
standard
method
result
environ
patient
male
femal
sampl
patient
colon
infect
total
sampl
obtain
horizont
surfac
air
sampl
settl
plate
sa
horizont
surfac
contact
plate
posit
eg
sampl
chair
air
sampl
posit
sa
settl
plate
conclus
high
proport
environment
sampl
taken
room
occupi
patient
mrsa
posit
repres
continu
sourc
endem
mrsa
enhanc
environment
clean
decontamin
especi
horizont
surfac
requir
reduc
airborn
spread
part
effect
programm
mrsa
control
four
thought
import
organ
bone
marrow
transplant
unit
ongo
outbreak
remain
nine
case
therefor
acquir
critic
care
unit
ventil
associ
pneumonia
epidemiolog
outbreak
investig
isol
genotyp
use
puls
field
gel
electrophoresi
pfge
risk
factor
associ
acquisit
identifi
mean
casecontrol
studi
extens
environment
screen
undertaken
reveal
multidrug
resist
p
aeruginosa
colonis
major
handwash
basin
drain
clinic
environment
isol
collect
indistinguish
pfge
review
ward
practic
reveal
respiratori
equip
includ
tracheostomi
tube
routin
rins
bedsid
handwash
basin
five
patient
acquir
organ
without
overlap
known
case
suggest
environment
reservoir
case
control
studi
identifi
number
signific
risk
factor
length
stay
presenc
tracheostomi
ventil
hour
prior
antipseudomon
therapi
multivari
analysi
howev
presenc
tracheostomi
remain
signific
consist
theori
transmiss
multiresist
p
aeruginosa
environ
patient
occur
tracheostomi
care
number
control
measur
employ
control
outbreak
success
includ
enhanc
hand
hygien
use
alcohol
gel
regular
disinfect
sink
hypochlorit
chang
practic
tracheostomi
care
introduct
staphylococcu
aureu
major
caus
hospit
acquir
bacteraemia
caus
signific
morbid
mortal
major
episod
secondari
intravascular
devic
ivd
studi
focus
ivd
type
complic
outcom
episod
ivd
relat
staphylococcu
aureu
bacteraemia
sehb
ireland
incorpor
one
region
three
gener
hospit
nine
month
period
method
prospect
studi
carri
nine
month
period
inform
obtain
episod
ivd
relat
staphylococcu
aureu
bacteraemia
result
episod
ivd
relat
staphylococcu
aureu
bacteraemia
nine
month
period
peripher
venou
devic
sourc
episod
central
venou
devic
sourc
episod
permcath
devic
sourc
episod
metastat
complic
occur
patient
death
directli
relat
staphylococcu
aureu
bacteraemia
occur
patient
conclus
prospect
studi
led
three
month
programm
focus
revis
implement
guidelin
insert
manag
intravascular
devic
subsequ
surveil
current
ongo
method
microbiolog
specimen
uhl
patient
yield
mrsa
select
patholog
computeris
databas
suscept
pattern
time
specimen
site
hospit
site
analys
macrolid
prescrib
inform
obtain
pharmaci
depart
result
total
patient
mrsa
period
proport
mrsa
sensit
erythromycin
es
strain
hospit
increas
hospit
b
hospit
c
three
hospit
chang
increas
proport
es
strain
isol
steril
site
blood
cultur
csf
etc
increas
suscept
test
method
remain
unchang
period
total
macrolid
usag
increas
period
limit
number
es
strain
phage
type
emrsa
annual
number
new
mrsa
posit
patient
increas
slightli
surprisingli
increas
proport
mrsa
isol
trust
suscept
macrolid
paradox
increas
erythromycin
suscept
occur
time
increas
macrolid
prescrib
increas
proport
invas
mrsa
suscept
erythromycin
similar
overal
chang
erythromycin
suscept
thu
evid
support
claim
increas
invas
potenti
es
strain
explan
chang
resist
method
retrospect
review
action
taken
respons
sar
multisit
bed
trust
employe
evalu
outcom
effect
result
patient
fulfil
diagnost
criteria
sar
admit
period
case
subsequ
confirm
mani
worri
patient
staff
dealt
e
telephon
consult
infecti
diseas
id
team
admit
first
case
id
unit
sar
polici
written
infect
control
team
ict
recommend
initi
manag
give
clear
instruct
referraladmiss
pathway
infect
control
precaut
occup
health
advic
staff
inform
review
daili
polici
redraft
necessari
close
liaison
occup
health
id
infect
control
microbiolog
human
resourc
educ
session
arrang
staff
plan
recruit
nurs
singapor
postpon
infect
control
doctor
particip
webbas
chat
hospit
intranet
site
allow
open
discuss
allevi
fear
occup
health
hotlin
set
staff
trust
work
relat
travel
queri
background
march
may
notic
increas
isol
multiantibiot
resist
e
cloaca
strain
ventil
patient
icu
isol
caus
invas
infect
strain
resist
gentamicin
broadspectrum
cephalosporin
quinolon
carbapenem
sensit
object
method
phenotyp
repres
sampl
isol
e
cloaca
use
api
antibiogram
analysi
estim
percentag
isol
carri
extendedspectrum
blactamas
esbl
genotyp
strain
e
cloaca
use
pulsedfield
gel
electrophoresi
pfge
macrorestrict
chromosom
dna
establish
singl
domin
clone
sever
clone
involv
outbreak
test
strain
demonstr
presenc
esbl
mast
dd
system
repres
sampl
phenotyp
subject
blashv
pcr
use
shvfor
shvrev
primer
four
strain
posit
blashv
gene
indic
product
shvtype
enzym
restrict
endonucleas
analysi
nhe
enzym
amplicon
confirm
point
mutat
shv
structur
gene
posit
glycin
serin
switch
indic
presenc
extendedspectrum
shvtype
blactamas
conclus
studi
demonstr
molecular
fingerprint
pfge
use
reliabl
epidemiolog
tool
investig
outbreak
caus
multiresist
e
cloaca
also
highlight
acquisit
esbl
may
one
altern
mechan
multiantibiot
resist
e
cloaca
strain
addit
chromosom
encod
cephalosporinas
method
retrospect
analysi
presumpt
infect
prosthet
joint
undergo
radiolog
biopsi
aid
diagnosi
patient
manag
specialist
musculoskelet
infect
unit
data
obtain
crossreferenc
microbiolog
databas
sunquest
persoft
inc
prospect
radiolog
histolog
databas
histolog
use
criterion
standard
diagnos
infect
conclus
prosthet
joint
biopsi
specif
sensit
diagnosi
pji
take
multipl
sampl
use
prolong
cultur
techniqu
may
improv
sensit
sensit
individu
sampl
approxim
advoc
take
least
two
biopsi
sampl
cultur
use
prolong
incub
send
materi
histolog
studi
also
highlight
difficulti
evalu
diagnost
test
robust
consensu
definit
infect
lack
studi
carri
determin
accur
incid
sternal
wound
infect
permit
earli
diagnosi
patient
follow
cardiothorac
surgeri
method
prospect
observ
studi
involv
assess
sternal
wound
follow
cardiothorac
surgeri
threemonth
period
carri
wound
assess
base
upon
wound
score
system
modifi
origin
score
system
devis
wilson
et
al
includ
erythema
paintend
serou
discharg
purul
discharg
wound
dehisc
posit
microbiolog
wound
infect
criteria
criterion
given
score
except
purul
discharg
posit
microbiolog
deep
swab
fluidtissu
carri
score
patient
assess
develop
wound
infect
discharg
hospit
risk
factor
investig
studi
determin
crude
wound
infect
rate
result
patient
cardiothorac
surgeri
period
coronari
arteri
bypass
graft
oper
cabg
patient
aortic
mitral
valv
replac
one
patient
ventricular
septal
defect
closur
one
aortic
root
replac
remain
patient
combin
procedur
nine
patient
found
wound
infect
give
crude
infect
rate
averag
stay
hospit
follow
surgeri
day
mean
durat
stay
develop
wound
infect
day
mean
time
diagnos
wound
infect
day
microorgan
isol
methicillin
sensit
staphylococcu
aureu
methicillin
resist
aureu
mrsa
coagulas
neg
staphylococci
enterococcu
spp
crude
infect
rate
sternal
wound
modifi
wound
score
protocol
easi
use
simpl
method
detect
wound
infect
earli
stage
data
collect
hip
arthroplasti
hospit
england
analys
estim
incid
surgic
site
infect
ssi
strength
associ
major
risk
factor
demograph
oper
infect
data
inpati
collect
prospect
fouryear
period
hospit
particip
nosocomi
infect
nation
surveil
servic
ninss
generalis
linear
model
use
estim
associ
potenti
risk
factor
ssi
allow
confound
incid
ssi
primari
total
hip
arthroplasti
primari
hemarthroplasti
revis
total
hip
arthroplasti
revis
hemiarthroplasti
respect
staphylococcu
aureu
identifi
ssi
methicillin
resist
mrsa
hemiarthoplasti
mrsa
caus
pathogen
ssi
ssi
superfici
involv
bone
joint
multivari
regress
analysi
identifi
age
group
trauma
durat
oper
asa
score
signific
independ
risk
factor
ssi
factor
taken
account
type
arthroplasti
signific
predictor
risk
ssi
allow
factor
still
signific
interhospit
variat
rate
ssi
still
evid
length
postop
stay
taken
account
patient
undergo
hemarthroplasti
older
higher
asa
score
like
surgeri
result
trauma
variat
incid
ssi
follow
hip
arthroplasti
like
explain
characterist
type
procedur
variat
incid
ssi
hospit
fulli
explain
casemix
comparison
rate
take
account
signific
risk
factor
methicillin
resist
staphylococcu
aureu
import
pathogen
ssi
hip
arthroplasti
especi
patient
undergo
hemiarthroplasti
background
issu
antibiot
prophylaxi
dental
work
presenc
joint
prosthesi
controversi
howev
advanc
dental
sepsi
requir
detect
treatment
prior
joint
replac
method
patient
non
bhaemolyt
streptococc
recov
revis
prosthet
joint
period
retrospect
review
predispos
factor
result
patient
viridan
streptococc
infect
detect
confirm
histolog
cultur
excis
arthroplasti
addit
patient
histolog
proof
infect
singl
isol
made
infect
joint
oxford
criteria
five
patient
continu
dental
sepsi
anted
last
joint
replac
one
preexist
radiat
proctiti
one
patient
mix
coagulas
neg
staphylococc
viridan
streptococc
infect
without
evid
dental
sepsi
patient
endocard
two
dental
patient
multipl
revis
mean
interv
patient
sinc
last
surgeri
year
dental
patient
requir
multipl
dental
extract
interv
excis
revis
arthroplasti
one
patient
broken
tooth
report
time
last
surgeri
receiv
reassur
one
overt
dental
abscess
fro
year
one
occult
dental
abscess
reveal
radiolog
two
other
extens
dental
cari
blacken
stump
teeth
followup
antibiot
treatment
revis
arthroplasti
limit
case
result
appear
satisfactori
conclus
look
mouth
routin
part
assess
prior
primari
joint
replac
oswestri
would
cardiac
surgeri
unit
patient
refer
centr
revis
arthroplasti
receiv
dental
examin
excis
arthroplasti
cultur
yield
viridan
streptococci
method
patient
initi
assess
aspir
prosthet
joint
cultur
histolog
measur
inflammatori
marker
patient
infect
basi
neutrophil
infiltr
excis
arthroplasti
one
patient
unassess
inflammatori
joint
diseas
one
histolog
omit
result
microbiolog
confirm
infect
aspir
oper
microbiolog
initi
aspir
yield
coagulaseneg
staphylococci
prove
fals
posit
judg
oper
histolog
cultur
initi
aspir
yield
fals
neg
result
assess
oper
cultur
patient
staphylococcu
aureu
haemolyt
streptococcu
recoveri
aspir
alway
predict
histolog
infect
cultur
often
neg
due
antibiot
mean
interv
excis
revis
arthroplasti
day
patient
grew
coagulaseneg
staphylococci
stage
multipl
sampl
three
neg
one
enterococc
infect
excis
one
previou
coagulaseneg
staphylococc
infect
one
previou
neg
excis
cultur
posit
aspir
develop
infect
subsequ
revis
five
patient
develop
sign
infect
followup
neg
oper
cultur
first
second
stage
revis
patient
least
month
follow
total
group
followup
month
one
patient
evid
recurr
organ
recov
initi
aspir
excis
arthroplasti
overal
satisfactori
outcom
achiev
overal
singl
revis
arthroplasti
conclus
vancomycin
therapi
excis
arthroplasti
may
restrict
durat
bacteriolog
aspir
second
stage
arthroplasti
poor
guid
definit
aetiolog
outcom
respect
method
retrospect
case
note
review
random
select
hiv
patient
note
review
gum
id
result
least
patient
sexual
histori
smoke
histori
taken
gum
patient
ask
recreat
drug
id
patient
depart
poor
record
vaccin
histori
past
histori
tuberculosi
risk
factor
heart
diseas
gum
patient
sexual
examin
screen
sexual
transmit
infect
sti
perform
compar
id
patient
id
patient
fundoscopi
perform
gum
depart
approxim
patient
blood
pressur
weight
record
less
patient
teeth
examin
greater
patient
baselin
count
viral
load
full
blood
count
renal
liver
function
test
record
id
like
perform
chest
xray
toxoplasmosi
cmv
screen
wherea
gum
like
perform
hsv
vzv
screen
team
poor
perform
baselin
lipid
glucos
patient
screen
hepat
b
c
depart
similar
result
hepat
id
patient
gum
patient
screen
conclus
differ
exist
two
depart
approach
newli
diagnos
hiv
patient
univers
new
patient
proforma
would
aid
equal
document
care
well
provid
audit
tool
face
new
bhiva
guidelin
background
outpati
manag
hiv
infect
patient
allow
screen
infect
malign
well
monitor
diseas
progress
adher
treatment
conduct
audit
review
aspect
care
conclus
substanti
differ
exist
approach
outpati
manag
screen
two
depart
depart
poor
repeat
screen
investig
assess
risk
sexual
transmit
infect
adher
medic
remind
proforma
introduc
clinic
outcom
audit
new
draft
guidelin
produc
british
hiv
associ
neither
antimalari
exhibit
signific
antihiv
activ
compar
sqv
select
index
vs
mq
cq
abl
significantli
increas
intracellular
hsqv
concentr
infect
cell
isobologram
construct
across
rang
concentr
reveal
antivir
synergi
sqv
mq
sqv
cq
final
effect
intracellular
accumul
hsqv
evalu
effect
upon
intracellular
sqv
concentr
cem
cell
howev
cem
cell
overexpress
pgp
intracellular
sqc
concentr
diminish
abl
almost
complet
restor
intracellular
sqv
accumul
think
lucki
get
peopl
come
smear
without
go
road
health
care
staff
state
increas
test
accompani
clear
concis
pct
guidanc
test
includ
obtain
inform
consent
perform
contact
trace
staff
felt
test
could
undertaken
famili
plan
clinic
cervic
smear
patient
receiv
inform
consult
altern
larger
practic
specif
chlamydia
clinic
could
held
conclus
effort
increas
chlamydia
screen
set
accompani
clear
guidanc
educ
appropri
financi
staff
resourc
gum
clinic
level
three
practic
gum
expertis
need
increas
provid
appropri
contact
trace
followup
introduct
diagnosi
genit
herp
difficult
without
take
viral
swab
onset
symptom
make
practic
kit
selfcollect
viral
swab
given
select
patient
method
kit
includ
steril
swab
viral
medium
distribut
individu
attend
genitourinari
medicin
clinic
histori
suggest
genit
herp
diagnosi
prove
difficult
kit
post
viru
laboratori
analysi
polymeras
chain
reaction
pcr
case
note
review
patient
inform
characterist
natur
durat
symptom
clinic
find
histori
examin
result
diagnost
test
analys
use
microsoft
excel
spss
softwar
result
patient
diagnos
hsv
type
hsv
type
diagnosi
made
selfcollect
kit
clinic
swab
greater
proport
symptomat
time
first
attend
clinic
versu
attend
longer
symptom
issu
kit
mean
versu
mean
week
took
longer
reach
diagnosi
mean
versu
mean
month
consult
clinic
mean
versu
mean
none
differ
statist
signific
patient
altern
diagnos
made
conclus
studi
illustr
difficulti
reach
diagnosi
genit
herp
innov
use
diagnost
techniqu
could
improv
manag
debilit
infect
work
warrant
investig
cost
effect
accept
selfcollect
kit
diagnosi
hsv
method
use
adjunct
test
convent
set
may
provid
swifter
flexibl
rout
diagnosi
manag
genit
herp
individu
background
attend
std
clinic
ireland
increas
dramat
recent
year
increas
incid
std
parallel
attende
age
twenti
compris
signific
proport
new
infect
method
januari
decemb
attende
std
clinic
age
less
twenti
follow
data
record
demograph
reason
attend
diagnos
risk
behaviour
std
conclus
peopl
twenti
increasingli
avail
std
clinic
femal
compris
larger
part
attende
attend
symptom
rather
screen
genit
wart
remain
commonest
reason
assess
incid
chlamydia
appear
trend
upward
low
level
condom
use
concern
substanc
misus
concern
sexual
gener
health
increas
increas
matern
antibodi
titr
x
p
mother
detect
dna
saliva
mean
viral
copi
number
copiesml
rang
preval
seroneg
women
women
highest
antibodi
titr
ci
preval
antibodi
children
mother
detect
saliva
mother
high
copi
number
saliva
ci
among
women
high
antibodi
titr
detect
dna
breast
milk
lower
level
saliva
mean
viral
copi
number
copiesml
rang
interpret
provid
evid
mothertochild
transmiss
matern
saliva
like
rout
commonli
cerebrospin
fluid
csf
patient
herp
simplex
hsv
enceph
mening
show
normal
glucos
level
case
herp
simplex
enceph
unusu
low
csf
glucos
present
also
review
previou
glucos
measur
hsv
pcr
posit
csf
sampl
taken
csf
glucos
rang
mmoll
mean
sd
ratio
csf
serum
glucos
rang
mean
sd
one
patient
csf
glucos
associ
hsv
mening
advent
molecular
diagnost
wider
spectrum
hsv
encephalitismening
recognis
seri
suggest
low
csf
glucos
valu
rule
diagnosi
background
adult
measl
gener
import
infect
uk
outbreak
measl
becom
increas
concern
reduc
uptak
mmr
case
report
year
old
indian
man
refer
infect
unit
one
week
histori
fever
cough
diarrhoea
rash
return
india
two
week
previous
admiss
note
erythemat
throat
cervic
lymphadenopathi
fever
widespread
maculopapular
rash
face
arm
trunk
leg
rash
initi
appear
face
hour
prior
admiss
investig
show
abnorm
liver
function
crp
mgl
normal
chest
xray
neg
malaria
film
spontan
resolut
fever
rash
next
day
serolog
measl
show
posit
measl
igm
neg
measl
igg
pcr
posit
measl
convalesc
serum
show
posit
measl
igm
igg
nine
day
discharg
prior
serolog
diagnosi
initi
patient
flatmat
admit
similar
histori
clinic
find
measl
diagnos
serolog
patient
student
stay
hall
resid
although
program
screen
vaccin
mmr
employ
public
health
one
student
admit
serolog
diagnos
measl
diagnosi
measl
consid
patient
maculopapular
rash
increas
risk
foreign
travel
countri
high
incid
measl
patient
clear
histori
vaccin
may
becom
increas
diagnosi
uk
given
recent
controversi
mmr
vaccin
program
norovirus
nv
common
caus
outbreak
gastroenter
particular
concern
healthcar
set
dako
enzym
immunoassay
eia
shown
sensit
specif
noroviru
diagnosi
compar
rtpcr
retrospect
analysi
evalu
laboratori
impact
chang
outbreak
investig
method
em
eia
collect
analys
data
consecut
winter
season
winter
faecal
specimen
outbreak
investig
nv
em
posit
specimen
outbreak
neg
em
also
examin
rtpcr
addit
specimen
found
posit
increas
posit
case
consequ
number
outbreak
diagnos
second
season
could
due
increas
sensit
eia
notic
increas
report
nv
outbreak
unit
kingdom
winter
season
could
explain
part
fact
mani
laboratori
probabl
introduc
sensit
diagnost
method
ie
eia
eia
less
labourintens
em
could
perform
frequent
abil
process
sampl
explain
notic
reduct
turnaround
time
two
season
background
object
steatosi
common
patient
chronic
hepat
c
viru
hcv
infect
thought
acceler
diseas
progress
viral
host
factor
report
influenc
format
steatosi
includ
obes
age
alcohol
consumpt
hcv
genotyp
address
rel
contribut
viru
host
factor
studi
patient
infect
genotyp
liver
biopsi
proven
chronic
hcv
data
variabl
avail
method
retrospect
analysi
patient
attend
region
hepat
c
servic
result
steatosi
found
liver
biopsi
patient
genotyp
patient
genotyp
univari
analysi
steatosi
correl
clinic
obes
bmi
age
alcohol
consumpt
hcv
genotyp
repeat
analysi
patient
bmi
steatosi
significantli
associ
genotyp
conclus
larg
cohort
patient
includ
patient
genotyp
infect
steatosi
strongli
associ
host
factor
obes
rather
alcohol
consumpt
genotyp
infect
may
influenc
steatosi
individu
clinic
obes
data
indic
risk
factor
nonalcohol
fatti
liver
diseas
nafld
need
address
patient
chronic
hcv
recent
emerg
diseas
affect
almost
million
peopl
worldwid
yet
knowledg
previou
travel
health
drug
adher
alcohol
intak
risk
behaviour
hcv
posit
travel
limit
method
prospect
questionnairebas
studi
patient
attend
joint
hepat
c
servic
newcastl
hospit
nh
trust
five
week
period
address
issu
travel
hcv
risk
behaviour
special
studi
modul
limit
time
patient
number
conclus
hcv
patient
travel
popul
often
ill
prepar
highrisk
behaviour
includ
unsaf
sex
drug
use
occur
whilst
travel
improv
care
hcv
travel
futur
pretravel
advic
specif
hcv
patient
promot
spring
term
becam
appar
outbreak
mump
among
student
univers
sheffield
hallam
univers
sheffield
total
case
seen
health
profession
januari
june
link
one
two
univers
attack
rate
rose
approxim
among
student
student
case
hospitalis
major
manag
local
depart
infecti
diseas
case
diagnos
clinic
present
parot
complic
precipit
admiss
hospit
includ
mening
orchiti
pancreat
oophor
laboratori
confirm
obtain
case
enzym
immunoassay
eia
mump
igm
blood
andor
detect
mump
viru
rna
sampl
saliva
throat
swab
cerebrospin
fluid
polymeras
chain
reaction
pcr
case
confirm
discontinu
outbreak
progress
cohort
student
current
higher
educ
born
earli
therefor
receiv
measl
mump
rubella
mmr
vaccin
introduc
student
howev
particularli
suscept
mump
viru
introduct
vaccin
reduc
herd
immun
due
natur
circul
viru
earli
epidem
outbreak
meet
call
decis
made
offer
mmr
vaccin
student
student
vaccin
separ
day
vaccin
centr
sever
complic
aros
result
vaccin
administr
present
overview
outbreak
brief
clinic
vignett
sever
complic
plu
graph
epidemiolog
epidem
background
hepat
hav
outbreak
uk
last
year
frequent
involv
inject
drug
user
idu
activ
immun
idu
propos
protect
gener
public
health
hepat
hav
pose
extra
risk
caus
superinfect
chronic
hepat
c
hcv
carrier
merseysid
idu
common
problem
hcv
preval
found
high
howev
littl
known
hav
make
difficult
plan
vaccin
guidelin
region
aim
assess
rate
hav
screen
idu
hospit
base
servic
document
rate
natur
immun
hav
method
retrospect
review
laboratori
databas
idu
seen
servic
posit
hcv
antibodi
test
tabul
hav
hepat
b
hbv
hcv
undertaken
result
hav
serolog
perform
hcv
posit
idu
overal
howev
popul
test
rose
screen
sinc
screen
polici
adopt
hav
igg
serolog
posit
hepat
b
surfac
antigen
posit
test
hav
hcv
conclus
hepat
screen
rate
low
still
need
improv
half
hcv
posit
idu
alreadi
immun
hav
might
affect
cost
calcul
immun
programm
includ
prevaccin
screen
although
result
subject
ascertain
bia
overal
conclus
like
similar
prospect
studi
diarrhoea
common
infect
children
result
death
million
children
everi
year
human
rotaviru
hrv
respons
death
diarrhoea
one
main
health
problem
iran
although
inform
pathogen
involv
studi
describ
aetiolog
viral
diarrhoea
characterist
hrv
shahrekord
iran
children
ys
admit
hajar
hospit
attend
primari
health
centr
shahrekord
acut
diarrhoea
children
hospitalis
elect
surgeri
select
octob
august
stool
sampl
collect
elisa
em
rtpcr
electropherotyp
virus
identifi
hrv
ten
hrv
identifi
children
without
diarrhoea
second
frequent
viru
coronaviru
case
follow
caliciviru
virus
includ
adenoviru
astroviru
parvoviru
hrv
frequent
identifi
children
year
old
rtpcr
success
type
hrv
g
type
p
type
frequent
p
type
p
sampl
p
p
non
ptypeabl
among
g
type
identifi
nongtyp
hrv
import
pathogen
caus
sever
diarrhoea
shahrekord
mark
season
variat
frequent
isol
novemb
februari
hrv
recov
result
agreement
studi
report
peak
hrv
winter
month
yearold
asymptomat
male
intraven
drug
user
six
year
ongo
care
addict
team
routin
screen
test
reveal
signific
elev
liver
transaminas
alanin
aminotransferas
alt
particularli
elev
despit
known
exposur
definit
hcv
posit
contact
high
index
suspicion
acut
hepat
c
viru
hcv
infect
addit
risk
factor
recent
tatoo
recent
episod
unprotect
sexual
intercours
upon
admiss
hospit
hepat
c
viru
hcv
screen
igg
antibodi
nonreact
howev
specimen
taken
day
weakli
reactiv
although
supplementari
assay
recombin
immunoblot
neg
day
igg
becom
posit
retrospect
realtim
quantit
polymeras
chain
reaction
pcr
amplif
rna
extract
specimen
refer
carri
pcr
posit
day
prior
seroconvers
observ
case
patient
follow
outpati
clinic
week
remain
hcv
rna
posit
decid
receiv
combin
antivir
therapi
pegyl
interferon
ribavirin
conclus
although
control
studi
target
approach
antifung
prophylaxi
appear
effect
reduc
incid
noninvas
invas
fi
children
ltx
howev
influenc
chang
antibacteri
policythat
may
affect
fungal
colonis
fiar
acknowledg
discuss
desferrioxim
therapi
incid
zygomycos
rise
due
increas
number
suscept
patient
diseas
rhinocerebr
pulmonari
cutaneoarticular
dissemin
rapidli
overwhelm
sepsi
high
mortal
rate
usual
surviv
associ
earli
diagnosi
aggress
surgic
debrid
high
dose
amphotericin
b
immunostimul
year
old
man
type
ii
dm
myelodysplast
syndrom
md
requir
regular
blood
transfus
regular
desferrioxim
infus
admit
fiveday
histori
pain
swollen
left
index
fingerth
site
use
blood
glucos
monitor
pu
finger
sent
microbiolog
cours
hour
patient
deterior
rapidli
die
despit
antimicrobi
therapi
postmortem
perform
result
postmortem
find
show
evid
fungal
septicaemia
infarct
kidney
spleen
brain
sever
pericard
necrotis
area
myocardium
sever
mening
thrombi
coronari
arteri
contain
numer
fungi
morpholog
fungi
histolog
stain
suggest
zygomycet
pu
patient
finger
yield
c
bertholletia
result
avail
post
mortem
conclus
case
highlight
rapid
invas
zygomycosi
progress
two
case
cutan
zygomycosi
acquir
inocul
due
c
bertholletia
report
previous
rais
possibl
infect
may
introduc
home
blood
glucos
monitor
case
patient
procedur
requir
particularli
risk
factor
may
increas
risk
infect
infect
diabet
foot
ulcer
dfu
staphylococcu
aureu
common
associ
increas
mortal
due
compromis
comorbid
whilst
elimin
nasal
carriag
aureu
known
use
health
protect
measur
patient
group
statu
role
diabet
mellitu
controversi
unknown
dfu
patient
therefor
sampl
anterior
nare
ulcer
dfu
outpati
isol
aureu
macrorestrict
sma
use
distinguish
match
ulcer
nasal
isol
individu
patient
control
healthi
individu
medic
student
institut
nasal
swab
taken
cultur
determin
baselin
carriag
rate
dfu
patient
nasal
carrier
aureu
one
patient
aureu
isol
ulcer
significantli
differ
control
carrier
dfu
isol
penicillinresist
compar
aureu
baselin
control
macrorestrict
determin
dfu
patient
nasal
carriag
strain
aureu
ulcer
posit
neg
predict
valu
nose
swab
simpl
measur
determin
whether
dfu
like
infect
respect
nasal
carriag
aureu
therefor
link
infect
dfu
protocol
erad
requir
protect
patient
infect
pcr
posit
cmv
diseas
infect
receiv
preemptiv
treatment
patient
pcr
surveil
receiv
aciclovir
prophylaxi
howev
patient
develop
cmv
diseas
mean
interv
transplant
cmv
pcr
posit
day
aciclovir
group
day
patient
receiv
prophylaxi
cost
manag
patient
cmv
accord
current
protocol
compar
highrisk
patient
receiv
ganciclovir
prophylaxi
caveat
patient
still
end
cmv
diseas
conclus
signific
differ
note
cost
manag
highrisk
patient
per
current
protocol
patient
receiv
ganciclovir
prophylaxi
instead
prophylact
aciclovir
prevent
cmv
diseaseinfect
may
delay
lncidenc
cmv
infectiondiseas
rate
advers
outcom
higher
expect
studi
group
object
evalu
protocol
cmv
surveil
preemptiv
treatment
oral
ganciclovir
cmv
mismatch
liver
transplant
protocol
complianc
doubt
consensu
whether
preemptiv
therapi
univers
prophylaxi
optim
approach
cmv
infect
method
retrospect
databas
analysi
casenot
review
liver
transplant
januari
perform
manag
cmvmismatch
patient
r
assess
agre
protocol
compris
regular
cmvqpcr
monitor
three
month
twiceweekli
inpati
weekli
follow
discharg
day
preemptiv
oral
ganciclovir
given
event
singl
high
viral
load
vl
copiesml
vl
increas
log
sequenti
sampl
therapeut
intraven
ganciclovir
indic
evid
cmv
diseas
result
liver
transplant
perform
cmv
mismatch
surviv
evalu
cmvqpcr
remain
develop
posit
titr
copiesml
posit
titr
evid
cmv
diseas
time
first
posit
vl
success
treat
intraven
ganciclovir
evid
cmv
diseas
initi
receiv
neither
preemptiv
therapeut
ganciclovir
given
intraven
oral
ganciclovir
remain
well
develop
seriou
cmv
diseas
delay
preemptiv
treatment
requir
intraven
ganciclovir
conclus
evalu
cmv
mismatch
agre
protocol
strictli
follow
case
remain
given
unnecessari
oral
iv
ganciclovir
complianc
protocol
poor
discharg
followup
outpati
distant
refer
centr
lead
delay
cmv
surveil
lack
confid
protocol
may
result
unnecessari
use
intraven
ganciclovir
follow
review
introduc
prophylaxi
oral
ganciclovir
day
cmvmismatch
liver
transplant
standard
proforma
use
collect
patient
data
includ
age
sex
primari
diagnosi
type
transplant
immunosuppress
therapi
respiratori
symptom
specimen
collect
laboratori
diagnosi
antimicrobi
agent
use
antivir
antibacteri
etc
outcom
infect
chi
squar
test
use
statist
calcul
data
collect
show
total
adult
patient
underw
transplant
unit
accept
patient
age
year
patient
infect
rhinovirus
account
viral
diagnosi
virus
present
includ
respiratori
syncyti
viru
rsv
influenza
para
influenza
piv
enterovirus
herp
simplex
cmv
infect
exclud
studi
adenoviru
infect
found
patient
rhino
viral
infect
discuss
report
frequenc
infect
due
rhinovirus
preval
higher
allogen
compar
autolog
recipi
total
death
directli
attribut
rhinoviru
respiratori
infect
respiratori
viral
infect
increasingli
report
import
caus
morbid
mortal
bone
marrow
transplant
bmt
recipi
recent
past
consider
experi
gain
regard
role
virus
includ
rsv
influenza
piv
adenovirus
howev
rel
littl
data
describ
role
rhinoviru
infect
patient
report
highlight
increas
import
rhinoviru
chest
infect
caus
morbid
mortal
bmt
patient
granulomat
amoeb
enceph
seriou
human
infect
almost
alway
lead
death
howev
pathogen
mechan
associ
diseas
remain
unclear
sever
line
evid
suggest
haematogen
spread
prerequisit
acanthamoeba
enceph
clear
circul
amoeba
cross
bloodbrain
barrier
gain
entri
central
nervou
system
recent
develop
vitro
bloodbrain
barrier
model
use
human
brain
micorvascular
endotheli
cell
use
model
determin
effect
acanthamoeba
enceph
isol
belong
genotyp
bloodbrain
barrier
permeabl
factor
respons
chang
observ
acanthamoeba
produc
increas
bloodbrain
barrier
permeabl
determin
whether
acanthamoeba
mediat
increas
permeabl
contactindepend
acanthamoeba
condit
media
produc
incub
bloodbrain
barrier
timedepend
increas
permeabl
observ
permeabl
within
h
incub
prior
treatment
condit
media
pmsf
serin
proteas
inhibitor
abolish
permeabl
chang
indic
role
serin
proteas
interest
alphamannos
inhibit
acanthamoeba
bind
human
brain
microvascular
endotheli
cell
increas
bloodbrain
barrier
permeabl
zymographi
assay
reveal
acanthamoeba
produc
three
distinct
proteas
two
inhibit
pmsf
conclus
first
time
shown
acanthamoeba
produc
bloodbrain
barrier
permeabl
block
pmsf
indic
potenti
role
serin
proteas
understand
mechan
associ
acanthamoeba
enceph
allow
us
develop
novel
strategi
prevent
seriou
infect
streptococcu
pneumonia
normal
resid
human
nasopharynx
nondiseas
state
respons
yet
unknown
trigger
invad
mucos
surfac
enter
bloodstream
caus
diseas
regul
activ
virul
gene
play
essenti
role
process
diseas
develop
character
pneumonia
regulatori
network
recent
area
interest
despit
inroad
littl
known
regul
virul
gene
pathogen
put
transcript
regul
pneumonia
mgra
homolog
virul
gene
activ
mga
group
streptococcu
ga
identifi
requir
develop
pneumonia
murin
model
work
confirm
mgra
requir
nasopharyng
carriag
pneumonia
transcript
profil
microarray
technolog
show
mgra
act
repressor
gene
rlra
pathogen
island
mediat
adher
respiratori
epitheli
cell
vitro
second
regul
within
island
rlra
activ
transcript
gene
interplay
two
regul
may
control
express
adhesin
respons
chang
host
environ
henc
alter
invas
andor
adhes
properti
bacteria
background
caspas
cystein
aspartatespecif
proteas
regul
cell
function
includ
program
cell
death
cytokin
process
cytoskelet
homeostasi
caspas
activ
contribut
poor
outcom
model
sepsi
method
human
monocytederiv
macrophag
mdm
murin
bone
marrowderiv
macrophag
bmdm
infect
type
pneumococci
spn
vitro
resolv
model
pneumococc
infect
mice
establish
apoptosi
quantifi
morpholog
dapi
stain
tunel
annexin
v
stain
caspas
inhibit
pancaspas
inhibitor
zvad
zfa
control
caspas
mice
investig
examin
specif
effect
caspas
activ
bacteri
coloni
count
quantifi
vitro
intracellular
kill
assay
vivo
blood
lung
homogen
howev
bacteri
internalis
vitro
inflammatori
cell
recruit
vivo
alter
bacteri
clearanc
cfulung
zvad
cfulung
control
greater
number
mice
bacteraem
p
caspas
defici
mice
show
alter
apoptosi
bacteri
clearanc
compar
wild
type
conclus
caspas
activ
associ
macrophag
apoptosi
induct
bacteri
kill
resolv
model
pneumococc
infect
apoptosi
induct
contribut
bacteri
clearanc
member
genu
shigella
pathogen
gastrointestin
gi
tract
human
caus
sever
sometim
fatal
bacillari
dysenteri
respons
approxim
one
million
death
annual
shigella
spp
invad
mucos
surfac
gastrointestin
tract
initi
acut
intens
inflammatori
reaction
lead
destruct
epithelium
breakdown
intestin
barrier
howev
far
less
known
bacterium
surviv
within
hostil
environ
gastrointestin
gi
tract
shigella
spp
must
extrem
adept
critic
initi
phase
pathogenesi
microorgan
given
oral
suffici
caus
diarrhoea
healthi
volunt
begun
investig
factor
flexneri
requir
colonis
gi
tract
analysi
librari
transposon
mutant
identifi
mutant
bacterium
unabl
caus
sustain
infect
rabbit
ileal
loop
valid
nonprim
model
intestin
shigellosi
sever
mutant
defect
lipopolysaccharid
lp
biogenesi
identifi
shown
strain
mark
truncat
lp
structur
unabl
withstand
bactericid
effect
antimicrobi
peptid
cecropin
complement
secret
gi
lumen
acut
infect
even
mutant
minor
chang
lp
unabl
glycosyl
antigen
repeat
subunit
gtr
mutant
also
defect
colonis
effect
depend
upon
invas
capac
bacterium
glycosyl
acetyl
antigen
basi
multipl
serotyp
shigella
spp
express
lp
essenti
surviv
gi
tract
differ
serotyp
shigella
spp
may
inher
differ
fit
surviv
host
therefor
gain
full
appreci
molecular
mechan
bacterium
evolv
success
inhabit
nich
host
examin
behaviour
n
meningitidi
human
tissu
explant
nasal
turbin
infect
n
meningitidi
bacteria
fail
penetr
epitheli
layer
identifi
isol
mutant
unabl
success
colonis
upper
airway
tissu
includ
two
express
pili
characteris
adhesin
meningococc
interact
epitheli
cell
also
recov
colonis
defect
mutant
insert
novel
gene
unknown
function
begun
analys
function
gene
express
recombin
protein
e
coli
determin
whether
heterolog
protein
mediat
bind
e
coli
host
cell
studi
interact
pathogen
bacteria
host
tissu
reveal
mechan
underli
colon
pathogenesi
use
model
reli
sole
immortalis
cell
aim
character
intern
process
clinic
isol
isogen
strain
mutat
superantigen
smez
streptococc
mitogen
exotoxin
z
mf
mitogen
factor
addit
isol
mutat
speb
ska
sl
slo
also
use
method
intern
assay
use
human
epitheli
cell
line
vitro
model
extracellular
bacteria
remov
wash
kill
antibiot
intern
mechan
investig
use
actin
cytoskeleton
inhibitor
integrin
subunit
block
antibodi
measur
cytox
epitheli
cell
cultur
media
remov
infect
ldh
measur
enzymat
assay
analysi
transcript
bacteri
rna
extract
desir
growth
phase
transfer
nitrocellulos
probe
dig
label
pcr
product
result
strain
exhibit
inoculum
depend
intern
intern
depend
actin
cytoskeleton
rearrang
integrin
subunit
interestingli
tnfb
inhibit
intern
loss
function
smez
gene
increas
isol
intern
also
increas
ldh
releas
epitheli
cell
smez
mutant
mark
enhanc
slo
transcript
paradox
strain
slo
associ
decreas
intern
increas
cytotox
conclus
contrari
publish
result
data
indic
serotyp
slo
may
key
factor
determin
intern
furthermor
factor
fibronectin
bind
protein
may
downregul
smez
adjac
regulatori
factor
rigor
system
investig
ga
intern
epitheli
cell
offer
platform
capac
screen
genomewid
mutant
pool
use
either
allcaus
pneumonia
efficaci
pneumococc
pneumonia
efficaci
ipd
efficaci
paediatr
otiti
media
efficaci
clyg
conclus
univers
paediatr
use
uk
would
prevent
death
clyg
highli
cost
effect
